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Despite decades of dedicated research, there remains a dire need for new drugs against
tuberculosis (TB). Current therapies are generations old and problematic. Resistance to
these existing therapies results in an ever-increasing burden of patients with disease that
is difficult or impossible to treat. Novel chemical entities with new mechanisms of action
are therefore earnestly required. The biosynthesis of coenzyme A (CoA) has long been
known to be essential in Mycobacterium tuberculosis (Mtb), the causative agent of TB.
The pathway has been genetically validated by seminal studies in vitro and in vivo. In Mtb,
the CoA biosynthetic pathway is comprised of nine enzymes: four to synthesize
pantothenate (Pan) from L-aspartate and a-ketoisovalerate; five to synthesize CoA from
Pan and pantetheine (PantSH). This review gathers literature reports on the structure/
mechanism, inhibitors, and vulnerability of each enzyme in the CoA pathway. In addition to
traditional inhibition of a single enzyme, the CoA pathway offers an antimetabolite strategy
as a promising alternative. In this review, we provide our assessment of what appear to be
the best targets, and, thus, which CoA pathway enzymes present the best opportunities
for antitubercular drug discovery moving forward.
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Despite a dramatic increase in innovative research over the last two decades, there remains a clear
and pressing need for new antitubercular drugs. Annually, 1.4 million people continue to die of
tuberculosis (TB), and the rates of drug resistant disease are on the rise “WHO MDR-TB Factsheet
2018” 2019; (World Health Organization, 2020). Caused by Mycobacterium tuberculosis (Mtb),
drug-susceptible TB is typically treated using a cocktail of drugs, including rifampicin and isoniazid
(World Health Organization, 2017). Mtb strains resistant to one or both of these two key TB drugs
are exceedingly difficult to treat. As resistance to current drugs is a clear issue, compounds with
mechanisms of action distinct from those of existing therapies are desperately needed.gy | www.frontiersin.org December 2020 | Volume 10 | Article 6056621
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A Biosynthesis in Mtb?
Cofactor biosynthetic pathways have drawn attention as
potential targets for antimicrobial drug development since the
demonstration that the sulfonamide class of antibacterials targets
the dihydropteroate synthase (DHPS) enzyme involved in the
biosynthesis of the B vitamin folate (Hammoudeh et al., 2013).
This interest hinges on two important factors: first, cofactors are
indispensable components of a wide range of metabolic reactions
that sustain life, and second, the biosynthesis of cofactors—
usually by biotransformation of a vitamin precursor—often
shows sufficient differences in the manner in which it occurs in
the pathogen compared to the human host that selective
targeting presents itself as an achievable goal. In addition, most
bacterial pathogens can produce the vitamin precursors through
de novo synthesis, while humans must obtain them from their
diet. This difference adds another layer of potential selective
pressure that may also prove useful in the pursuit of cofactor-
targeting antimicrobials.
It is therefore unsurprising that the biosynthesis and
utilization of the enzyme cofactor coenzyme A (CoA, 1) and
its vitamin B5 precursor pantothenate (Pan, 2) have a long
history as targets in antimicrobial drug research, with the first
studies following very close on the discovery of the sulfonamide
antibacterials (Spry et al., 2008; Moolman et al., 2014; Wellington
and Hung, 2018). As an enzyme cofactor, its use is unparalleled,
with an estimation that up to 9% of all enzyme activities use CoA
in one of its forms (Strauss, 2010). The most important of these
are the enzymes involved in central carbon metabolism (itself an
important potential target in Mtb (Rhee et al., 2011), and the
large number of enzymes that use CoA as the acyl carrier for
transfer of acyl groups in fatty acid and polyketide biosynthesis
(Mercer and Burkart, 2007), as well as in signaling and regulation
pathways relying on acetylation-based switches (Pietrocola
et al., 2015).
CoA and Pan first drew attention in antituberculosis (antiTB)
drug research with the report of a study of viable vaccine candidates
that an Mtb mutant auxotrophic for Pan—due to the double
deletion of the panC and panD genes involved in Pan
biosynthesis—showed significantly lower virulence than the wild
type strain, and that mice infected with this strain lived significantly
longer (Sambandamurthy et al., 2002). This finding strongly
indicated that in the host–pathogen interaction, Mtb is dependent
on its own biosynthesis of Pan for optimal fitness, and also
identified two enzymes that could potentially be targeted to
achieve this through pharmacological intervention. The two
enzymes in question, aspartate decarboxylase (ADC or PanD)
and pantothenate synthase (PS or PanC), are responsible for the
last steps of Pan biosynthesis, forming b-alanine 3 from L-aspartate
4 and coupling it to pantoate 5 (Figure 1A) (Strauss, 2010). The
latter is a unique hydroxy acid formed by sequential action of
ketopantoate hydroxymethyl transferase (KPHMT or PanB) and
ketopantoate reductase (KR or PanE). This discovery sparked a
large drug discovery effort aimed at finding inhibitors of PanC, and
led to further interest in Pan and CoA biosynthesis as viable antiTB
drug targets.Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 2The CoA Biosynthetic Pathway Is Essential
in Mtb—But Does This Mean the Enzymes
Are Good Drug Targets?
Like in other bacteria, the biosynthesis of CoA from Pan in Mtb
occurs in five enzymatic steps catalyzed by four proteins, with one of
these being bifunctional (Figure 1B) (Strauss, 2010). The pathway
starts and ends with ATP-mediated phosphorylation reactions
catalyzed by pantothenate kinase (PanK or CoaA) and
dephospho-coenzyme A kinase (DPCK or CoaE). These reactions
bracket the introduction of the key thiol group used in the acyl
group carrying reactions through the coupling and subsequent
decarboxylation of L-cysteine by phosphopantothenoylcysteine
synthetase (PPCS) and decarboxylase (PPCDC) respectively, two
enzyme activities harbored by the bifunctional CoaBC protein. The
adenylyl group is introduced by phosphopantetheine
adenylyltransferase (PPAT or CoaD). All of these enzymes are
required for the de novo biosynthesis of CoA from Pan and have
been shown to be essential (Sassetti et al., 2003; Ambady et al., 2012;
DeJesus et al., 2017). Moreover, as no evidence exists that intact
CoA can be obtained from the host, each enzyme presents itself a
priori as a potential target for antiTB drug development.
However, recent findings in CoA biology have shown that
CoA may in fact be obtained in other ways—although the
physiological relevance of these alternative pathways is entirely
dependent on the organism and its environmental context
(Sibon and Strauss, 2016). For example, a salvage pathway
exists in which the CoA breakdown product pantetheine
(PantSH, 6) can serve as an advanced precursor for CoA
synthesis (Figure 1C). However, the ability of an organism
(including Mtb) to obtain CoA through the salvage of PantSH
depends on three factors: first, availability of PantSH in the
environment; second, pathways by which it can be taken up; and
third, ability of the organism’s PanK to act on PantSH as an
alternative substrate to transform it directly into 4′-
phosphopantetheine (P-PantSH, 7), thereby bypassing the need
for the reactions catalyzed by CoaBC (Figure 1C). In addition, it
has been demonstrated that in some organisms P-PantSH can be
taken up to allow for the formation of CoA only through the
action of PPAT and DPCK (Srinivasan et al., 2015). Finally,
Mtb’s DPCK is unique in that it is fused to a domain of unknown
function, which could impact on its regulation and activity
(Walia and Surolia, 2011). Clearly, the target assessment of
individual CoA biosynthetic enzymes in Mtb is complex and
cannot be reduced to a simple gene essentiality analysis.
Hijacking CoA Biosynthesis: Using
CoA Antimetabolites as Inhibitors
Apart from targeting one or more of the Pan or CoA biosynthesis
enzymes directly for inhibitor development, a promising
alternative is to use structural analogues of the respective
pathway precursors, their intermediates or the final products,
as inhibitors. Such an antimetabolite strategy is based on the
closely related structures interfering with one or several CoA
biosynthesis or CoA-dependent enzymes, leading to
bacteriostasis or bactericidality (Shapiro, 2013). The effective
use of antimetabolites as antibacterials dates back to GerhardDecember 2020 | Volume 10 | Article 605662
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synthetic antibacterial, as its structure resembles that of p-
aminobenzoic acid (the natural substrate of DHPS) and
therefore acts as a competitive inhibitor of the enzyme
(Hammoudeh et al., 2013).
Indeed, following the discovery of the antifolates, several
structural analogues of Pan were prepared with the view of
achieving a similar outcome (Spry et al., 2008). This led to the
discovery and testing of pantoyltaurine 13 and its amides 14 for
antibacterial activity (Figure 2A). Interestingly, one of the results of
this study was the discovery that many antimetabolites mimicking
the structure of Pan are actually accepted and transformed by the
CoA pathway enzymes to form active inhibitors (Moolman et al.,Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 32014). In some cases, the target is one of the CoA biosynthetic
enzymes. An example of this mode of inhibition is the fungal
natural product CJ-15,801 15 that inhibits PPCS after it has been
phosphorylated by PanK to give 16 (Figure 2B). In other cases, the
Pan antimetabolite is fully transformed by PanK, PPAT and DPCK
into CoA antimetabolites that lack the crucial thiol group on which
its activity is based. This is the situation for the N-heptyl
pantothenamide N7-Pan 17 (Figure 2C). Consequently, such
compounds can have a multi-pronged inhibitory effect: first, by
competing with natural precursors of CoA during its biosynthesis,
thereby reducing the rate of its formation, second by leading to the
build-up of intermediates of the pathway that could allosterically
inhibit the pathway enzymes through feedback mechanisms, thirdA
B
C
FIGURE 1 | Biosynthesis of pantothenate (Pan, 1) and coenzyme A (CoA, 1). (A) Biosynthesis of Pan 2 proceeds in four steps (blue block): the decarboxylation
of L-aspartate 4 by aspartate decarboxylase (PanD/ADC) to give b-Ala 3, the hydroxymethylation of a-ketoisovalerate (3-methyl-2-oxobutanoate, 8) by
ketopantoate hydroxymethyltransferase (PanB/KPHMT) to form ketopantoate 9, and subsequent reduction of 9 by ketopantoate reductase (PanE/KR) to yield
pantoate 5. In the final step, b-Ala 3 and pantoate 5 are coupled by pantothenate synthetase (PanC/PS) using ATP as intermediate activator to produce Pan 2.
(B) CoA 1 is formed from Pan 2 in five steps (green block), the first being the ATP-mediated phosphorylation of Pan by pantothenate kinase (CoaA/PanK) to
form 4′-phosphopantothenate (P-Pan, 10). P-Pan is then coupled to L-cysteine with the aid of cytidine triphosphate (CTP) as activator to form
4′-phosphopantothenoylcysteine (P-PanCys, 11), which is then decarboxylated to give 4′-phosphopantetheine (P-PantSH, 7). The transformation of P-Pan into
P-PantSH is achieved by the PPCS and PPCDC enzymes, which are found on the bifunctional CoaBC protein. Adenylylation by phosphopantetheine
adenylyltransferase (CoaD/PPAT) to form dephospho-coenzyme A (DePCoA, 12) and its ATP-mediated phosphorylation by dephospho-coenzyme A kinase
(CoaE/DPCK) completes the pathway. (C) P-PantSH 7 can also be formed directly by PanK acting on the CoA degradation product pantetheine (PantSH, 6) as
an alternative substrate (yellow block). This allows for the salvage biosynthesis of CoA in three steps using only PanK, PPAT, and DPCK.December 2020 | Volume 10 | Article 605662
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natural pathway intermediates, and lastly by forming CoA
analogues that act as inhibitors of a range of CoA-dependent
enzymes. Since CoA also serves as source of the 4′-
phosphopantetheine group of the holo-acyl carrier protein (ACP)
involved in fatty acid biosynthesis, CoA antimetabolites can have
multifaceted impact on cellular physiology. However, the rational
design of such inhibitors poses a special challenge as not only must
their interactions with the putative CoA-utilizing targets be
optimized, but the ability of their precursors to act as reasonable
substrates for the CoA biosynthetic enzymes should also be
considered. This difficult balancing act is not easily achieved.
Providing a Context for CoA-Directed
Antituberculosis Drug Development
As indicated above, while every enzyme taking part in Pan and
CoA biosynthesis may present itself as a potential target for
inhibitor development based on gene essentiality analysis, within
the context of Mtb biology and the specific conditions under
which Mtb survives and proliferates in the human host, not each
enzyme is an equally vulnerable target. This review aims to not
only give an overview of the inhibitor discovery work that has
already been performed on each of the enzymes, but to also
provide an assessment of their suitability as drug targets, i.e., the
likelihood that small molecule inhibitors could be translated into
viable new antiTB therapies based on the insight gained fromFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 4experimental studies performed on these proteins to date. Our
target assessment leans heavily on studies of conditional
knockdown mutants of the genes encoding each of the Pan
and CoA biosynthetic enzymes as performed by Mizrahi and co-
workers; these studies provide a more nuanced perspective on
target vulnerability by studying the impact of reducing the
endogenous levels of each of the enzymes in question on Mtb’s
rate of growth and its virulence in mouse infection models
(Abrahams et al., 2012; Evans et al., 2016). Our analysis also
aims to complement that of a comprehensive in silico drug target
identification pipeline in Mtb, called targetTB (Raman et al.,
2008). This pipeline incorporates the analyses of the protein-
protein interactome, the reactome’s flux balance, experimentally-
derived phenotype essentiality data and the target sequences, as
well as an algorithm-based structural assessment of targetability.
In addition, the potential of Pan and CoA antimetabolites as
new antiTB drugs will also be highlighted, focusing on cases
where CoA pathway enzymes have been shown to be inhibited by
such compounds, or where they are known to be required for the
metabolic activation of antimetabolite precursors to their active
inhibitor forms. In light of the prevailing use of parameters
reporting the inhibition of isolated enzymes (such as IC50 or Ki)
as the primary criterion or driver in inhibitor development and
screening efforts, we also attempted to provide information on
how well this translated to observed whole cell inhibition (as
reported by minimum inhibitory concentrations, or MICs).A B C
FIGURE 2 | Pan and CoA antimetabolites. (A) Pantoyltaurine 13 and its amides 14 were some of the first Pan antimetabolites tested for antibacterial activity. (B) The
fungal natural product CJ-15,801 15 is a Pan antimetabolite that is activated via phosphorylation by PanK; its phosphate 16 subsequently inhibits PPCS. (C) Pan
antimetabolites that are structurally similar to the CoA degradation product PantSH 6 can hijack the CoA salvage pathway enzymes to be transformed into CoA
antimetabolites. For example, the pantothenamide N7-Pan 17 is phosphorylated by PanK to form 18, which is then converted into 19 by PPAT and DPCK. These
compounds can inhibit the biosynthesis of CoA in several ways, e.g., by competing with the natural substrates for access to the biosynthetic enzymes, by causing
the build-up of biosynthetic intermediates that may regulate the enzymes through feedback inhibition, and by causing such feedback inhibition directly by mimicking
the structures of the intermediate. Meanwhile, the CoA antimetabolites themselves can inhibit any CoA-dependent enzyme.December 2020 | Volume 10 | Article 605662
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level view of antiTB drug development targeting Pan and CoA-
related biology in Mtb.TARGETING PANTOTHENATE
BIOSYNTHESIS
The discovery that a Pan auxotrophic Mtb strain is highly
attenuated in immunocompromised mice led to the launch of
several inhibitor discovery initiatives in the context of antiTB
drug development. The majority of these were focused on the
PanC enzyme, not only because the panC gene was one of those
deleted in the Pan auxotroph, but also for medicinal chemistry
reasons as detailed below. However, this section will describe the
current status of our knowledge of each of the Mtb Pan
biosynthetic enzymes as potential targets for drug development.
PanB – Ketopantoate
Hydroxymethyltransferase (KPHMT)
PanB Enzyme Structure and Mechanism
Ketopantoate hydroxymethyltransferase (KPHMT), also known as
3-methyl-2-oxobutanoate hydroxymethyltransferase in many
databases, is encoded for by the panB gene (Rv2225) in Mtb to
give the Mtb PanB enzyme (MtPanB). It is the first enzyme in the
Pan biosynthetic pathway and transforms a-ketoisovalerate (3-
methyl-2-oxobutanoate, 8) to ketopantoate (2-dehydropantoate,
9) through transfer of a hydroxymethyl group provided by N5,
N10-methylenetetrahydrofolate (N5,N10-CH2-THF) cofactor in the
presence of a metal ion (Teller et al., 1976; Powers and Snell, 1976;
Powers and Snell, 1979). The metal acts as a catalyst in the
formation of the enol intermediate that leads to the formation of
the new C–C bond. PanB has the greatest preference for Mg2+ but
can also use other metals such as Mn2+, Zn2+, Co2+, Ni2+, and Ca2+
with the rate of enolization, kenol, decreasing by approximately a
third for Zn2+ and Co2+ and nearly 15-fold for Ni2+ and 32-fold for
Ca2+. The kenol of a-ketoisovalerate was measured through
monitoring the exchange of the b-hydrogen by NMR
spectroscopy (Powers and Snell, 1976; Sugantino et al., 2003).
From studies on the PanB enzymes from Escherichia coli and
Salmonella enterica serovar Typhimurium, there is some evidence
of feedback inhibition by end products within the pathway
including Pan 2 (500 µM), CoA 1 (1 mM) and pantoate 5 (50
µM), as evidenced by increased KM and lower Vmax values at
concentrations greater than those specified (Powers and Snell,
1976; Rubio and Downs, 2002). However, the physiological
relevance of such a feedback inhibition mechanism requires
further investigation and seems unlikely as these concentrations
exceed those normally encountered in cells.
Three catalytic mechanisms have been proposed and are
discussed and contrasted in a previous review of the pathway
(Webb et al., 2004). The kinetic constants forMtPanB have been
determined by using a spectrophotometric assay that couples
ketopantoate production to the consumption of NADPH by
using the next pathway enzyme, ketopantoate reductase (PanE)
(Sugantino et al., 2003). The determined parameters were a KMFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 5(a-ketoisovalerate) of 240 µM and a kcat value of 47 min-1, which
is comparable to that seen for the E. coli enzyme (Powers and
Snell, 1976; Sugantino et al., 2003).
Apart from the initial characterization studies, few other
investigations on MtPanB have been reported. Its crystal
structure was solved in 2003 but since then no new data have
been published (Chaudhuri et al., 2003). The enzyme’s
quaternary structure exists as a decamer consisting of two
pentameric rings stacked on top of each other (Figure 3A).
Although based on the b/a (TIM) barrel fold, its structure
contains several unique modifications (Sugantino et al., 2003;
Chaudhuri et al., 2003). These include slightly different
positioning of some of the a-helices that form the outer rim of
the barrel and replacement of one helix by a coil. There are also
modifications at the N-terminus. Additionally, one of the a-
helices in the C-terminal region is slightly longer than usual and
spans two different monomers from opposite pentameric rings.
This domain swapping—which is unique among those PanB
enzymes that have been characterized structurally—results in
covering of the exposed hydrophobic surface of the opposing
barrel, and is obvious when compared to the structure of the E.
coli homologue, EcPanB (Figure 3B). The active site lies at the
top of the barrel within a deep cleft formed between the interface
of the subunits from the pentameric ring and the residues here
are highly conserved across the family (Chaudhuri et al., 2003).
Assessing PanB as a Drug Target
No known inhibitors of any PanB homologue have been
identified or designed yet. The only compounds showing some
inhibition of PanB’s activity are analogues of 8 that are missing
either its carboxyl group, its a-carbonyl function or both methyl
groups (Powers and Snell, 1976). The in silico target
identification pipeline, targetTB, identified MtPanB as a high
confidence target (Raman et al., 2008); in support of this,
knockdown of panB was shown to cause bacteriostasis (Evans
et al., 2016). Taken together, this suggests potential for MtPanB
inhibitors as antiTB agents. However, any inhibitor design
initiative would require careful elucidation of the active site
binding interactions and the proposed feedback inhibition
mechanisms. This is particularly important as the b/a (TIM)
barrel fold is a common structural motif used by several enzymes
that are mechanistically similar to PanB, suggesting that selective
inhibition of MtPanB may be difficult to achieve through
strategies aimed only at the discovery of competitive inhibitors.
Instead, compounds that exploit the proposed feedback
mechanism could prove more valuable starting points, as these
are more likely to be specific to MtPanB.
PanC – Pantothenate Synthetase (PS)
PanC Enzyme Structure and Mechanism
Pantothenate synthetase (PS), the product of the panC gene
(Rv3602c), catalyzes the Mg2+- and ATP-dependent
condensation of pantoate 5 and b-alanine 3 to form Pan 2
(Figure 1A) (Spry et al., 2008). Mechanistically, the PS-catalyzed
reaction proceeds in two sequential steps. The first step involves
activation of pantoate’s carboxylic acid through adenylylation.
The resulting reactive pantoyl adenylate intermediate (20)December 2020 | Volume 10 | Article 605662
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in the second step, resulting in the release of AMP and the Pan
product (Zheng and Blanchard, 2001; Pandey et al., 2018). Mtb
PanC (MtPanC) has been well characterized both structurally
and kinetically, with crystal structures of the enzyme in its apo
form, as well as in complex with several substrates, inhibitors,
and reaction intermediates (Zheng and Blanchard, 2001; Wang
and Eisenberg, 2003; Zheng et al., 2004; Wang and Eisenberg,
2006; Pandey et al., 2018). The enzyme’s activity is typically
measured using an assay that couples the production of AMP to
the oxidation of NADH using myokinase, pyruvate kinase and
lactate dehydrogenase. Using this assay, Zheng and Blanchard
confirmed that MtPanC requires Mg2+ and has a Bi Uni Uni Bi
Ping Pong kinetic mechanism similar to that reported for the E.
coli homologue (Miyatake et al., 1978), with KM (pantoate) of 130
µM, KM (b-Ala) of 800 µM, KM (ATP) of 2.6 mM and a kcat value
of 3.4 s-1 (Zheng and Blanchard, 2001).
The large amount of structural and mechanistic data available
for MtPanC has allowed elucidation of the active site and
characterization of essential binding site interactions. Previous
studies have confirmed that the enzyme is a member of the
cytidylyltransferase superfamily (Wang and Eisenberg, 2003;
Wang and Eisenberg, 2006). Its structure reveals a homodimer,
with each subunit consisting of 290 amino acid residues totalingFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 633 kDa. The subunits have two defined domains, a large N-
terminal domain that forms a Rossmann fold (residues 1–186),
and a smaller C-terminal domain that incorporates a three-
stranded antiparallel b-sheet with a helical layer above it
(Wang and Eisenberg, 2003; Wang and Eisenberg, 2006).
As commonly seen in nucleotide binding proteins, the active
site of MtPanC is located on the N-terminal domain. It appears
toward the end, within the central parallel b-sheet and is partially
covered by b-strands from the C-terminal domain. The bottom
of the active site is primarily hydrophobic, in contrast to the top
half of the cavity, where several charged residues are located
(Wang and Eisenberg, 2003). These residues are important for
binding ATP, and also participate in catalysis. Additionally, four
arginine residues covering the active site cavity form a positively
charged region and are thought to attract the negatively charged
substrates (i.e., ATP and pantoate) to the active site (Wang and
Eisenberg, 2003).
Interestingly, in contrast to that seen for the E. coli
homologue EcPanC, the relative positions of the two domains
of MtPanC remain unchanged in structures of the enzyme in
complex with eight different substrates/reaction intermediates.
This difference was attributed to MtPanC having extensive
interactions between the N- and C-terminal domains, many of
which would not be present in EcPanC if it formed a similarA
B
FIGURE 3 | Subunit and oligomeric structures of PanB proteins. (A) Structure of MtPanB (PDB: 1OY0) showing from left to right the monomer subunit, the
interaction of two opposing subunits via the extended a-helix in the C-terminus, and the native decamer consisting of two stacked pentameric rings. A Mg2+ ion
(magenta ball) bound at the top of the b/a (TIM) barrel defines the location of the active site. (B) Same views of EcPanB (PDB: 1M3U) to highlight the differences in
subunit interactions in the constitution of the native decamer. The stick structure of ketopantoate 9 bound in the active site of EcPanB is indicated by an arrow.December 2020 | Volume 10 | Article 605662
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consequence of this difference is that substrates can diffuse into
the MtPanC active site without the need of domain movement.
In the case of EcPanC, it was postulated that opening and closing
of the active site occurs because of a hinged movement of its C-
terminal domain. Conversely, it is possible that the flexible
region of the MtPanC C-terminal domain (residues 75 to 88)
functions as a gate to its active site cavity (Wang and Eisenberg,
2003). This claim is supported by the observation that these gate
residues are disordered when the MtPanC active site is occupied
by both AMPCPP and glycerol, or pantoate alone, but becomes
ordered upon formation of the pantoyl adenylate intermediate
(Wang and Eisenberg, 2003; Wang and Eisenberg, 2006).
PanC Inhibitors Developed Through Rational Design
The three-dimensional structure of MtPanC in complex with
pantoyl adenylate (20) demonstrates that the reaction
intermediate has several polar interactions with active site
residues (Figure 4). These strong interactions are essential in
stabilizing the highly reactive intermediate, forcing the molecule
to adopt a nearly linear conformation, thereby allowing it to
adequately occupy the bottom of the active site cavity. This
binding mode suggests that unreactive analogues mimicking the
structure of the pantoyl adenylate reaction intermediate could
act as potent inhibitors of MtPanC with high affinity and
specificity (Wang and Eisenberg, 2003; Ciulli et al., 2008; Xu
et al., 2014).
There are two reported studies conducted to date that explore
the use of unreactive pantoyl adenylate analogues as inhibitors of
MtPanC, one being a set of sulfamoyl adenylates, and the other a
series of acyl-sulfamate and sulfamide mimetics (Table 1) (Ciulli
et al., 2008; Xu et al., 2014). To prevent decomposition by
intramolecular lactonization, all analogues lacked either the
terminal hydroxyl or the carbonyl group of the pantoyl moiety.
Co-crystal structures of MtPanC complexed with each of three
sulfamoyl adenylate analogues were reported by Ciulli et al.
(2008). The authors found that the compound structurallyFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 7most similar to the pantoyl adenylate intermediate (20) had
the greatest potency across the two series, displaying nanomolar
dissociation and inhibition constants. All three sulfamoyl
analogues were found to act as competitive inhibitors towards
pantoate. Likewise, the series of acyl-sulfamates and sulfamides
reported by Xu et al. (2014) was also found to bind competitively
with respect to pantoate.
The co-crystal structures produced by Ciulli et al. (2008)
allowed for binding mode elucidation and identification of many
key binding interactions within the pantoate pocket. The
carbonyl and hydroxyl groups of compound 21 (Table 1) form
hydrogen bonds with two conserved glutamine residues at the
pantoate binding site. These interactions are not observed with
related derivatives in this series (compounds 22 and 23),
resulting in a 10-fold reduction in binding affinity. The authors
postulate that this can be attributed to the exchange of the
hydroxyl group with an amine in compounds 22 and 23, as the
introduction of the amine group changes the hydrogen bond
donor/acceptor interactions with the two glutamine residues
(Ciulli et al., 2008). Consequently, this leads to a disruption of
the hydrogen bond network between three active site residues
that are conserved across all bacterial PS enzymes and are known
to be essential for enzyme activity (Zheng et al., 2004). Through
further structural elucidation, a number of other key features
within the pantoate pocket were identified, with plans to test the
most potent compound for activity in a cell-based assay against
Mtb (Ciulli et al., 2008).
In comparison, the series of adenylate mimics synthesized by
Xu et al. (2014) were designed to function as bisubstrate
inhibitors that bind both the pantoate and ATP binding
pockets (compounds 24-28, Table 1). These inhibitors were
designed to use an acyl-sulfamate or -sulfamide as a
bioisosteric replacement for the labile acyl phosphate moiety
present in the native intermediate. In addition, the inhibitors
display structural modifications at the terminal hydroxyl group,
carbonyl group, and ribose ring. Compound 24, with an acyl-
sulfamate linkage and a natural ribose moiety, was found to beA B
C
FIGURE 4 | (A) Structure of pantoyl adenylate intermediate 20. (B) Binding interactions of pantoyl adenylate in the active site of MtPanC [PDB: 1N2I (S. Wang and
Eisenberg, 2003)]. (C) Hydrogen bonding interactions of compound 24 in the active site of MtPanC, demonstrating the bisubstrate functionality of these compounds
with the pantoate binding pocket shown in yellow and the ATP binding pocket shown in blue [figure modified from (Xu et al., 2014)].December 2020 | Volume 10 | Article 605662
Butman et al. Targeting Coenzyme A in MtbTABLE 1 | Structures and inhibition characteristics of MtPanC inhibitors developed through rational designa.
Entry R Ki (µM) MIC (µM)
21
0.22 ± 0.03 –
22
4 ± 0.6 –
23
18 ± 3 –
24
0.27 ± 0.04 > 250
25
1.73 ± 0.24 > 250
26
0.99 ± 0.30 > 250
27
0.87 ± 0.12 > 250
28
3.47 ± 0.48 > 250Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 8 December 2020 | Volume 10 | ArticaCompounds 21 – 23, reported by (Ciulli et al., 2008), are competitive inhibitors with respect to ATP; MtPanC inhibition was determined using a PK/LD coupled kinase assay. Compounds
24 – 28, reported by (Xu et al., 2014), are competitive inhibitors with respect to pantoate; MtPanC inhibition was determined using the MesG coupled assay and Mtb whole-cell screening
was carried out against wildtype H37RvMA and a MtPanC-depleted strain. All values are shown as reported in the original studies.le 605662
Butman et al. Targeting Coenzyme A in Mtbthe most potent, while sulfamide 28 was the least potent.
Modifying the ribose moiety in 24 to arabinose (compound
25) led to a marked loss in affinity. Molecular docking studies
revealed that high binding affinity is contingent upon the
presence of the secondary hydroxyl and carbonyl groups,
which are necessary in forming critical hydrogen bond
contacts with the two highly conserved glutamine residues at
the pantoate binding site, a finding in agreement with previous
studies (Ciulli et al., 2008; Xu et al., 2014). Unfortunately, the
compounds in this study were inactive against Mtb in whole cell
assays, as well as against a panC knockdown strain (Xu et al.,
2014). The authors attribute this lack of potency to poor cell
penetration or possible efflux as the most probable causes,
concluding that PanC may not be an ideal antimycobacterial
drug target due to low vulnerability to inhibition.
A fragment-based approach that combines both fragment
growing and fragment linking methods in the development ofFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 9MtPanC inhibitors has been employed by a number of groups
(Hung et al., 2009; Sledz et al., 2010; Silvestre et al., 2013). For
example, the fragment growing approach was used by Hung et al.
(2009) who elected to initiate the process using a methoxy-
substituted indole derivative (compound 29), known to act as an
ATP-competitive ligand (Table 2). Incremental structural
modifications were made to compound 29 at the C2 and N1
positions of the indole ring, and the resulting compounds were
evaluated in relation to the initial fragment. After several
constructive iterations, this method led to the identification of the
acyl sulfonamide inhibitor 30 with a Ki value of 27 µM. A fragment
linking approach was used when it was found that benzofuran
analogue 31, which was first identified from a thermal-shift screen,
binds to the active site of MtPanC in a considerably different
manner than compound 29. The ternary complex structure of
MtPanC and both compounds 29 and 31 showed little movement
of the molecules in relation to their initial positions, and minorTABLE 2 | Structures and inhibition characteristics of MtPanC inhibitors developed through fragment-based approachesa.






0.28 1.5 Fragment growing
31
0.34 1000 Thermal-shift screen
32
0.26 1.8 Fragment linking
33
0.30 0.2 Group efficiency analysis
34
0.28 – Group efficiency analysisDecember 2020 | VoaCompounds 29–32 were reported by (Hung et al., 2009) and 33 and 34 were reported by (Hung et al., 2016). Both series of compounds are competitive inhibitors with respect to ATP,
and KD values were determined from titration experiments using ITC.lume 10 | Article 605662
Butman et al. Targeting Coenzyme A in Mtbconformational changes of the target, suggesting that they may be
linked to obtain a higher affinity ligand. To join the two fragments—
while maintaining their initial binding modes—a variety of linkers
were introduced and assessed. A significant increase in potency was
observed when an acyl sulfonamide linker was used, giving rise to
analogue 32 that had a Ki value of 9 µM and a ligand efficiency (LE)
of 0.26. Interestingly, the indole ring and the acyl sulfonamide
present in both compounds 30 and 32 were found to bind in an
identical manner, whereas the 4-methylpyridine ring in compound
30 occupies the b-alanine binding pocket, and the benzofuran ring
in compound 32 binds to the pantoate pocket. Overall, the
discovery of the two remarkably similar compounds with
comparable potencies demonstrated that the two different
fragment-based ligand discovery strategies—fragment-growing
and fragment-linking—can successfully be applied to the
development of inhibitors of MtPanC (Hung et al., 2009).
Unfortunately, none of these compounds showed inhibition of
the growth of wild-type Mtb, but all inhibited the panC
conditional mutant, confirming that they were on target.
Compound 32 showed the strongest effect, correlating with its
activity as the most potent MtPanC inhibitor (Abrahams
et al., 2012).
In a second paper, Hung et al. (2016) further optimized
compounds 30 and 32 by implementing a group efficiency (GE)
analysis, allowing different structural components within each
molecule to be more closely examined and the binding
contributions (DDG) to be determined. As a result, this approach
was used to efficiently highlight specific moieties within the
molecules responsible for inefficient binding, enabling further
modifications. Both the indole fragment and acetate substituent
were shown to contribute significantly to overall binding. InFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 10contrast, insufficient binding contributions were identified for the
methyl pyridine and benzofuran groups, thus replacement of these
moieties was explored. The acyl sulfonamide linker also showed
limited contributions to binding; however, this group is essential to
retain the non-hydrolyzable linkage and was thus retained. A series
of ten indole acyl sulfonamides was synthesized and evaluated,
resulting in several compounds with sub-micromolar activity
against MtPanC. In particular, compound 33 (Table 2), with a
highly electronegative trifluoromethyl substituent, was found to be
the most potent inhibitor in this series with a KD value of 200 nM
and an IC50 value of 5.7 µM. Additional crystallographic studies of
the four most potent compounds were used to further probe the
deep pocket of the MtPanC P1 site. The authors hypothesized that
the addition of a methylene group between the sulfonyl and
aromatic moieties would facilitate the movement of the aromatic
ring to belowMet40, causing a substituent in the para position to be
pushed into the back of the P1 pocket (Hung et al., 2016). This led to
the design of compound 34 (Table 2), a para-trifluoromethyl-
substituted benzylsulfonamide, which showed favorable
hydrophobic bonding interactions with residues deep in the P1
site, confirming the anticipated inhibitor requirements for this
favorable binding orientation to occur. Compound 34 showed a
significant increase in potency againstMtPanC in comparison to 33,
with an IC50 value of 250 nM. This study demonstrates the utility of
a fragment-based approach proceeded by lead optimization of hit
fragments in developing potent inhibitors. Furthermore, the ability
to identify the binding distribution of a given compound based on
GE analysis allows for the modification of specific groups, thus
leading to more potent inhibitors.
In a more recent structure-based study, a series of thiazolidine
derivatives as inhibitors of MtPanC were developed usingTABLE 3 | Structures and inhibition characteristics of MtPanC inhibitors developed through energy-based pharmacophore modelinga.
Entry R1 R2 IC50 (µM) MIC (µM)
35
1.12 ± 0.12 54.81
36
0.35 ± 0.01 1.55
37
0.37 ± 0.02 1.71December 2020 | Volume 10 | ArticaCompounds 35–37 were reported by (Devi et al., 2014). MtPanC inhibition was determined using a PK/LD coupled kinase assay, and Mtb whole-cell screening was carried out against
wildtype H37Rv cells by using the MABA method. All values are shown as reported in the original study.le 605662
Butman et al. Targeting Coenzyme A in Mtbenergy-based pharmacophore (e-pharmacophore) modeling (Table
3). Devi et al. (2014) began by using the crystal structure ofMtPanC
in complex with pantoyl adenylate to generate an energetically
optimized, structure-based pharmacophore by using Phase software
(Dixon et al., 2006). This e-pharmacophore was then used to carry
out a high throughput virtual screen of a 500,000-compound
library. Selected hits were synthesized and tested in vitro against
MtPanC, where seven compounds displayed > 60% inhibition at 25
µM. The most potent was compound 35, a thiazolidine derivative
containing a benzodioxo group and a 3-pyridyl moiety, with an IC50
of 1.12 µM (Devi et al., 2014). Further analysis revealed four
hydrogen-bonding interactions and polar contacts between 35
and active site residues of MtPanC, as well as a similar overall
orientation to that of the native ligand. A second set of 19
compounds were designed and synthesized in order to explore
the SAR around compound 35, in which the benzodioxo position
was modified with a variety of substituted phenyl rings, and the 3-
pyridyl group replaced with phenyl, naphthyl, and other pyridyl
groups. Many of the compounds displayed submicromolar activity
against MtPanC, while only six compounds had MIC values <10
µM (Devi et al., 2014). Two of the most active inhibitors
(compounds 36 and 37) were selected to undergo further
investigation. These compounds were found to display improved
activity against MtPanC (IC50 value of 350 nM for 36) and against
Mtb cells (MIC value of 2 µM for 36). In addition and importantly,
compounds 36 and 37 also display activity against dormant Mtb
cells (Devi et al., 2014).
PanC Inhibitors Identified by Screening
Several inhibitors that target MtPanC have been identified
through various screening methods (White et al., 2007;
Velaparthi et al., 2008; Yang et al., 2011; Kumar et al., 2013;
Ntie-Kang et al., 2013; Samala et al., 2013; Naidu et al., 2014;
Samala et al., 2014; Naidu et al., 2016; Naidu et al., 2016;
Amaroju et al., 2017; Pradhan and Sinha, 2018; Kumar et al.,
2019; Hassan et al., 2020; Singireddi et al., 2020). White et al.
(2007) developed an automated high-throughput screen (HTS)
by adapting the coupled assay first used by Zheng and Blanchard
(2001), and used it to identify known drugs that inhibitMtPanC.
A diverse library of 2880 compounds containing drugs across a
wide range of therapeutic areas, experimentally bioactive
molecules, and natural products was surveyed. Twenty-nine
compounds showed some activity based on IC50 values; these
were rescreened against the coupling enzymes to confirm their
specificity for MtPanC. Only nafronyl oxalate (compound 38,
Table 4) was identified as a specific inhibitor of MtPanC,
showing competitive inhibition with a Ki of 75 µM, one-fifth
that of the substrate’s KM. A co-crystal structure ofMtPanC with
38 was compared to the crystal structure of MtPanC complexed
with pantoyl adenylate. This showed that the two molecules were
positioned similarly in the active site of MtPanC, but a more
favorable hydrogen-bonding network was established between
the pantoyl adenylate intermediate and the MtPanC active site.
Unfortunately, even though this compound showed promising
competitive inhibition, it was found to be inactive against Mtb in
a whole cell assay.Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 11In a similar set of studies, Kumar et al. (2013) developed an
enzyme-based assay that modified previously established PanC
coupled assays relying on absorbance. The standard coupled
assay was modified to account for any autofluorescence occurring
in compound libraries by generating a fluorescent signal that could
be measured as the endpoint of the assay. This assay was then used
to carry out anHTS on a large and extensive library of nearly 100K
compounds. Using this screen, two 3-biphenyl-4-cyanopyrrole-2-
carboxylic acid analogues were selected for further evaluation
(compounds 39 and 40, Table 4). Both compounds were active
against purified recombinant MtPanC and were shown to inhibit
growthofMtb, howeverbothalso displayed somedegree of toxicity.
Conditional knockdown studies were conducted to determine the
specificity of compounds 39 and 40. The results were consistent
withPanC-mediated inhibition, attributing thegrowth inhibitionof
Mtb to on-target activity against PanC.This data suggested that this
scaffold could be further developed for improved potency
against Mtb and decreased toxicity to mammalian cells (Kumar
et al., 2013).
More recently, a molecular docking approach was employed by
Pradhan and Sinha (2018) to screen a library of 154 small molecule
containing amides known to inhibit pantothenate synthetase. In
silico predictive results from this screen identified a sulfonamide
analogue theorized to inhibit the enzyme, exhibiting significantly
better docking scores than two approved sulfa drugs. Unfortunately,
due to the lack of in vitro results, this compound could not be
analyzed in relation to other similar compounds. A pharmacophore
model was generated based on enzyme-ligand interactions
established in the docking studies, providing insight into the
binding mode of the sulfonamide analogue in the active site of
MtPanC. Furthermore, a molecular dynamics simulation study was
carried out, with the corresponding predicted energy profile
signifying the formation of a stable conformation upon enzyme-
ligand binding (Pradhan and Sinha, 2018). In conjunction, the use
of computational predictions as well as the continued exploration of
amide analogues has further contributed in the development of
novel antituberculars (Pradhan and Sinha, 2018).
In another virtual screening study, Yang et al. (2011)
developed a novel HTS approach to discover potent MtPanC
inhibitors. They began by screening a small (~3000) library of
compounds in a manner similar to the HTS performed by White
et al. (2007), and identified actinomycin D (compound 41, Table
4) as a weak inhibitor ofMtPanC, with an IC50 of 251 µM (Yang
et al., 2011). To discover more potent inhibitors, the molecular
mechanism of inhibition of 41 was determined by circular
dichroism and fluorescence quenching. This allowed for the
construction of a pharmacophore, followed by a virtual
screening of 20K compounds based on these identified
structural features. This approach led to the identification of a
potent indole-containing MtPanC inhibitor (compound 42,
Table 4) with an IC50 of 22 µM, a ten-fold improvement in
activity compared with compound 41 (Yang et al., 2011).
Additionally, compound 42 was active against wild-type Mtb,
with an MIC of 54 µM. Collectively, this study details a new
method, based on confirmed inhibitor-enzyme interactions, for
exploring potential lead compounds.December 2020 | Volume 10 | Article 605662
Butman et al. Targeting Coenzyme A in MtbAs many current antitubercular drugs contain some form of
nitrogen heterocycle, a series of hybrid molecules containing a
pyrazine scaffold was recently investigated by Hassan et al.
(2020). The compounds were designed to incorporate a
pyrazine ring with either a carbohydrazide linker or a bioactive
heterocyclic moiety. A preliminary in silico screen solely based
on the structural formula of these compounds was performed to
predict their biological potential. The predicted hits were tested
in vitro against Mtb H37Rv using the microplate alamar blue
assay (MABA), resulting in the identification of six compounds
that displayed significant activity, with MIC values ranging from
0.78 µg/mL to 6.25 µg/mL and no cytotoxicity (compounds 43–
48, Table 5) (Hassan et al., 2020). Further investigation ofFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 12these structures revealed that the compounds containing a
carbohydrazide linker between the pyrazine ring and a second
heterocyclic moiety exhibited the greatest potency against Mtb. A
target fishing approach was employed on the most active
analogue (compound 44) to elucidate the mechanism of action
and identify the target responsible for the observed whole cell
activity. This was carried out computationally using a shape-
based similarity study, pharmacophore mapping, and inverse
docking. Together, the results of these studies suggest that
MtPanC is the target responsible for the activity of these
inhibitors (Hassan et al., 2020).
In a similar study, Amaroju et al. (2017) developed a series of
compounds by implementing a molecular hybridizationTABLE 4 | Structures and inhibition characteristics of MtPanC inhibitors developed through high throughput screeninga.
Entry Structure Ki (µM) IC50 (µM) MIC (µM)
38
75 ± 13 – > 13
39
1.8 ± 1.1b 0.174 ± 0.02 115
40
4.0 ± 1.1b 0.297 ± 0.037 54
41
(actinomycin D)
– 250.72 ± 39.69 –
42
1.4 22.44 ± 1.55 54December 2020 | Volume 10 | ArticaCompound 38, reported by (White et al., 2007), is a competitive inhibitor with respect to ATP; MtPanC inhibition was determined using a PK/LD coupled kinase assay. Compounds 39 and 40,
reported by (Kumar et al., 2013), are competitive inhibitors with respect to ATP as determined using the same coupled assay. Mtb whole-cell screening was carried out against wildtype H37Rv cells
and against a MtPanC conditional knockdown strain. Compounds 41 and 42 are reported by (Yang et al., 2011). Compound 42 is a competitive inhibitor with respect to ATP and Mtb whole-cell
screening was carried out against wildtype H37Rv cells. All values are shown as reported in the original studies.
bEC50 values are reported.le 605662
Butman et al. Targeting Coenzyme A in Mtbapproach based on the structures of two previously reported
MtPanC inhibitors (Samala et al., 2014; Naidu et al., 2016). In
prior work, twenty-six pyrazole and triazole compounds were
synthesized. Compounds were tested for in vitro enzymeFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 13inhibition against MtPanC and in vitro whole cell activity
against three Mtb strains. The most active compound
contained a 4-methoxyphenyl substituent on the triazole
moiety (compound 49, Table 5) with an IC50 of 1.01 µM andTABLE 5 | Structures and inhibition characteristics of MtPanC pyrazine analogues developed through in vitro screeninga.














24.72December 2020 | Volume 10 | ArticaCompounds43–48, reportedby (Hassan et al., 2020),were evaluated for in vitro activity againstMtbH37Rv strain using theMABAmethod.Compound49was reportedby (Amaroju et al., 2017)
and evaluated againstMtbH37Rv strain (aswell as twostrainsextracted from tuberculosis patients, the results ofwhich arenot shownhere). All values are shownas reported in theoriginal studies.le 605662
Butman et al. Targeting Coenzyme A in Mtban MIC of 25 µM against wild-type Mtb (Amaroju et al., 2017).
Consequently, compound 49 was found to be more active against
both MtPanC and Mtb whole cells than the pyrazole derivative
after which it was designed. This potency, in combination with
the low cytotoxicity displayed, shows the potential for further
antimycobacterial development based on this core structure
(Amaroju et al., 2017). The triazole scaffold was further
explored more recently, where a series of molecules linking a
quinazolinone to a 1,2,3-triazole were examined (Kumar et al.,
2019). Unfortunately, these compounds displayed only moderate
activity against Mtb.
Assessing PanC as a Drug Target
In summary, although an extensive amount of structural and
mechanistic information is available for MtPanC, no adequate
clinical candidates have been reported to date. Many of the
compounds designed and evaluated have shown low to
submicromolar inhibition of MtPanC, but overall failed to
establish significant whole cell inhibition. This outcome may
be explained by the results of the targeted knockdown studies of
the Pan and CoA biosynthetic enzymes, which showed that
reducing MtPanC levels to >95% slowed cell growth, but did
not arrest it (Abrahams et al., 2012). This would indicate that
MtPanC is a relatively invulnerable target in the context of Mtb
drug development, and that MtPanC-directed inhibitors would
have to show near complete inhibition of the enzyme’s activity
before it would impact on cell growth. Nonetheless, the
compounds discussed in the studies above have provided a
considerable foundation for development of inhibitors active
against Mtb. Moreover, as the targetTB comprehensive in silico
target identification pipeline recognized MtPanC as a high
confidence target, interest in this enzyme remains high (Raman
et al., 2008). Within this context MtPanC remains a viable and
attractive target for selective antitubercular drug development,
with the important caveat that prospective inhibitors would have
to show high affinity binding or long residence times before they
could be considered for further investigation.
PanD – Aspartate Decarboxylase (ADC)
PanD Enzyme Structure and Mechanism
PanD, or aspartate decarboxylase (ADC), catalyzes the formation
of b-alanine 3 from L-aspartate 4 via a decarboxylation reaction
as its name implies (Figure 1A). Unlike most other
decarboxylases that depend on a pyridoxal phosphate (PLP)
cofactor for catalysis, PanD is one of a few enzymes that make
use of an enzyme-bound pyruvoyl-group that is revealed after a
post-translational cleavage step. In the case of Mtb PanD
(MtPanD, encoded by panD (Rv3601c)), the protein is first
expressed as a 15.95 kDa pro-enzyme known as the p-protein
that undergoes autocatalytic cleavage to form the active enzyme
consisting of a smaller b-subunit and a larger a-subunit with the
N-terminal pyruvoyl group (Chopra et al., 2002; Gopalan et al.,
2006). The p-protein consists of seven b strands, two 310 helices
and two a helices that form a double y, b barrel (Gopalan et al.,
2006). The autocatalytic cleavage of the p-protein occurs
optimally at 37°C and goes to completion after 48 hours. As
this roughly mirrors the doubling time and growth temperatureFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 14of Mtb, the maturation process has been suggested as a
mechanism of regulating the production of b-Ala 3 (Chopra
et al., 2002). The crystal structure of the unprocessed p-protein is
available (PDB ID: 2C45), and the mechanism of cleavage, which
occurs at an internal serine, has been elucidated (Ramjee et al.,
1997; Albert et al., 1998; Gopalan et al., 2006; De Villiers
et al., 2010).
Interestingly, while size-exclusion chromatography (SEC)
and X-ray crystallographic analysis indicate that MtPanD
exists as a tetramer (Figure 5A) (Gopalan et al., 2006; Sun
et al., 2020), small angle X-ray scattering (SAXS) studies show
that it forms a monodispersed octamer (stacked tetramers) in
solution (Gopal et al., 2020). The Arg54 residue along with the
pyruvoyl group are key actors within the active site, which is
found at the interface of adjacent subunits of the tetramer.
Specifically, Arg54 aids in substrate recognition through
formation of a salt bridge with Asp’s b-carboxylate, while the
pyruvoyl group forms a transient imine with its amino group to
serve as an electron sink that facilitates its decarboxylation
(Sharma et al., 2012a; Sharma et al., 2012b).
MtPanD’s steady state kinetic parameters were determined by
utilizing a discontinuous assay that monitors the conversion of 4 to
3 through generation of fluorescamine derivatives of each species,
followed by HPLC analysis (Ramjee et al., 1997; Chopra et al., 2002).
The KM was found to be 219.6 µM and the kcat 0.65 s
-1.
PanD Inhibitors Developed Through Rational Design
De Villiers et al. (2010) set out to design mechanism-based
inhibitors that capitalize on the differences between PLP- and
pyruvoyl-dependent decarboxylases to obtain compounds that
are selective forMtPanD. For this purpose, they tested L-erythro-
3-fluoro-asparate (50) and its L-threo epimer (51) and found that
instead of being turned over catalytically, these substrate
analogues underwent single-turnover decarboxylation, followed
by elimination of fluoride (Figure 5B). This sequence produced
enamine adducts that could be trapped within the active site (De
Villiers et al., 2010). When the L-erythro epimer 50 was used, the
resulting adduct was stable enough that it could be observed even
without trapping; the result was rationalized based on the
presence of the fluorine causing stabilization of the enamine
adduct. However, in a kinetic assay, only the L-threo epimer 51
showed inhibition of MtPanD activity because only its
conformation was predicted to closely mimic that of the
natural substrate when bound to the active site. Unfortunately,
insufficient material was produced to test whether these
compounds showed any activity against Mtb in growth assays;
however, considering the reactive nature of a-fluorinated amino
acids, it is likely that this compound would also affect
other targets.
PanD Inhibitors Identified by Screening
Sharma and co-workers used a cheminformatics approach to
identify potential inhibitors of MtPanD (Sharma et al., 2012b;
Sharma et al., 2012a). Using crystal structures of PanD enzymes
from Thermus thermophilus and Helicobacter pylori with substrates
bound in the active site, they found that these overlapped with the
active site of the processed MtPanD to within 1 Å. TheyDecember 2020 | Volume 10 | Article 605662
Butman et al. Targeting Coenzyme A in Mtbsubsequently used the Schrödinger software suite to perform a
high-throughput virtual screen of compounds for binding to the
model of the MtPanD active site. Three public ligand libraries
(Maybridge, NCI and FDA) totaling over 333K compounds were
used in the screen, which resulted in the identification of 803 hits. A
more refined screen was performed using Glide’s Extra Precision
(XP) mode, resulting in 28 compounds being selected for
pharmacokinetics analysis using Qikprop. From these, seven lead
compounds were identified as the most suitable candidates for
further testing and investigation (Sharma et al., 2012b; Sharma et al.,
2012a). An additional seven inhibitors previously identified against
EcPanD were also tested (Williamson and Brown, 1979; Sharma
et al., 2012a). While prior inhibition assays made use of the
previously mentioned discontinuous assay that depends on
fluorescamine derivatization of reaction mixtures, a simpler, direct
and label-free assay was used for this study that relied on an NMR
spectroscopy-based protocol that measured the formation of b-Ala
3 from L-Asp 4 directly (Sharma et al., 2012a). All inhibitors were
tested at 1 mM using 1 mM L-Asp and 2.83 mM MtPanD, and
results were processed by comparing the % conversion of the
inhibited reaction at the time point at which the uninhibited
reaction reached 50% conversion. Krel was subsequently calculated
by comparing the ratio of % conversion with and without
inhibitor (if unchanged Krel = 1.0). The six most promising
inhibitors identified in this manner (those with Krel ≤ 0.4) were
all simple organic acids, including oxaloacetate (the most potent
of the inhibitors tested), b-hydroxyaspartate, L-glutamate and bothFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 15D- and L-tartrate. The observed inhibition was rationalized to be
mainly due to competitive binding to the enzyme active site through
formation of non-specific electrostatic interactions.
PanD as a Target for Pyrazinamide
Pyrazinamide (PZA, 52) has long been used as part of the
standard combination therapy to treat Mtb. However, its
primary target has yet to be definitively confirmed. A detailed
review describing the current knowledge of PZA’s mode of
action (MoA) (Gopal et al., 2019) and a paper that analyses
the various proposed mechanisms and results (Anthony et al.,
2018) have recently been published. Here, the focus will be on the
information pertinent to MtPanD, considering several recent
findings that have highlighted its involvement in PZA’s MoA.
PZA is a prodrug and is activated by the pyrazinamidase
PncA to pyrazinoic acid (POA, 53) (Figure 5C) (Scorpio and
Zhang, 1996; Via et al., 2015; Lanoix et al., 2016; Yadon et al.,
2017; Naftalin et al., 2017). A variety of targets have been
suggested for PZA/POA throughout the years; however, there
is an increasing amount of evidence thatMtPanD is likely at least
one of these targets. This is supported by both the in vitro and in
vivo isolation of resistant mutants of PZA with missense
mutations in panD (Shi et al., 2014; Gopal et al., 2016; Gopal
et al., 2017b; Gopal et al., 2019). Two main proposals have been
made on how the active inhibitor (POA) affectsMtPanD activity
(Gopal et al., 2019). The first suggests that POA binding to
MtPanD inhibits its ADC activity, leading to an observedA B
DC
FIGURE 5 | PanD structure and inhibitors. (A) Top and side views of the tetrameric structure of MtPanD as determined by X-ray crystallography (PDB: 6OYY), with each
processed p-protein (i.e., consisting of a- and b-subunits) shown in a different color. The C-terminal extension, which is unique to MtPanD among PanD proteins, is not
resolved in the determined structure, but would be attached to the portion indicated in the dashed oval. (B) 3-Fluorinated L-aspartates (50 and 51) act as alternative substrates
of MtPanD, but undergo only single turnover followed by fluoride elimination. Depending on the epimer used, this results in the formation of either cis- or trans-enamines, which
are transiently trapped in the enzyme’s active site. (C) Structure of the antiTB agent pyrazinamide (PZA, 52), which is activated through hydrolysis to form pyrazinoic acid (POA,
53). (D) Active site of MtPanD showing the binding mode of POA (PDB: 6OYY); its hydrogen bonding interactions with the indicated active site residues are shown with black
dashed lines. The pyruvoyl group (Pyr) that is required for catalysis is shown in the left foreground.December 2020 | Volume 10 | Article 605662
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and CoA levels (Gopal et al., 2016; Gopal et al., 2017a). This
proposal is supported by several studies confirming the binding
of POA to MtPanD (Shi et al., 2014; Dillon et al., 2014; Gopal
et al., 2017a), including a crystal structure showing POA bound
in the enzyme’s active site (Figure 5D) (Sun et al., 2020). This
proposed MoA is supported by the finding that the two best-
studied resistant mutations cause amino acid exchanges in the
enzyme’s active site loops (Zhang et al., 2013; Shi et al., 2014;
Gopal et al., 2017b). The second proposal is based on the finding
that PZA resistant mutants also showed missense mutations in
the gene encoding the unfoldase ClpC1, suggesting that upon
binding of POA, MtPanD’s C-terminal protease degradation tag
is exposed to a greater extent (Figure 5A) (Gopal et al., 2019;
Gopal et al., 2020). Since ClpC1 binds and transports proteins to
the ClpP protease, increased exposure of the tag leads to a greater
amount of MtPanD to be recognized by ClpC1 and degraded by
ClpP (Raju et al., 2012; Yamada and Dick, 2017; Gopal et al.,
2019; Gopal et al., 2020).
Whether PanD is the primary target of PZA (52) remains a
matter of debate for several reasons. First, the incidence of PZA
resistant clinical isolates with mutations in panD is low (Maslov
et al., 2015; Werngren et al., 2017; Coll et al., 2018; Gopal et al.,
2019), second, several other likely and mechanistically plausible
targets have been identified, and finally, results demonstrate that
a PanD loss-of-function auxotrophic Mtb mutant is still
vulnerable to POA when supplemented with PantSH, i.e.,
when the deleterious effects due to defects in Pan synthesis
(and therefore CoA biosynthesis) have been alleviated (Dillon
et al., 2014; Anthony et al., 2018; Gopal et al., 2019).
Assessing PanD as a Drug Target
The targetTB in silico target identification pipeline did not
identify MtPanD as a high confidence target (Raman et al.,
2008). It was excluded from the list of targets as the structural
assessment of targetability indicated likely structural homology
between its identified binding pockets and those identified in the
human proteome, suggesting that the design of selective
inhibitors might be difficult to achieve. However, as this
analysis was done using generally applied algorithms, an
investigation of the known MtPanD binding sites might
indicate otherwise. In addition, no targeted knockdown of
panD has been conducted to date—the main reason being that
the adjacent panC and panD genes are positioned so close to one
another that it would not be possible to effectively reduce the
translation of one without also affecting the other. As such, it is
likely that the results of the targeted knockdown of panC at least
partially reflects the impact on knockdown of panD as well
(Abrahams et al., 2012).
However, the combination of the lower virulence of the double
DpanCDmutant, and the higher survival rates of mice infected with
this strain (Sambandamurthy et al., 2002), together with recent
findings that tie PZA’s antiTB MoA to effects related to MtPanD,
make a strong case for this enzyme as a promising candidate for
further drug design efforts (Gopal et al., 2019; Gopal et al., 2020).
Moreover, western blot and shotgun proteomic analyses indicateFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 16that the intrabacterial concentration ofMtPanD is low compared to
the other Pan and CoA biosynthetic enzymes (Gopal et al., 2020).
PanE – Ketopantoate Reductase (KPR)
Enzyme Structure and Mechanism
PanE, the ketopantoate reductase (KPR) enzyme specifically
responsible for reduction of ketopantoate 9 to D-pantoate 5
(Figure 1A), long remained elusive. Its identification was
complicated, in part, due to several other enzymes being
capable of catalyzing this reduction (Webb et al., 2004).
Ketopantolactone reductase is one such example, along with
enzymes isolated from both Candida parapsilosis and spinach
chloroplasts (King et al., 1974; Hata et al., 1989; Julliard, 1994;
Webb et al., 2004). The first sample with KPR activity was
purified in 1988 (Shimizu et al., 1988), and the structure of the
apo enzyme from E. coli was solved in 2001 (Matak-Vinković
et al., 2001). Crystal structures of E. coli PanE with the NADP+
cofactor bound, and the ternary complex with NADP+ and 5,
have since been characterized (Lobley et al., 2005; Ciulli et al.,
2007). The PanE enzymes of S. enterica Typhimurium,
Stenotrophomonas maltophilia and E. coli have been studied
(Webb et al., 2004). Kinetic parameters have been rigorously
investigated for E. coli PanE, leading to an ordered sequential
kinetic mechanism being proposed for the enzyme (Zheng and
Blanchard, 2000a; Zheng and Blanchard, 2000b; Zheng and
Blanchard, 2003).
To date, there is very little information available for the Mtb
PanE homologue (MtPanE). The activity of the protein expressed
by the putative panE gene (Rv2573) has not been experimentally
verified, although its crystal structure bound to NADP+ and
oxamate has been solved (PDB ID: 4OL9).
PanE Inhibitors
The native cofactor has been used as a template for fragment-
based targeted binding to identify hot spots within the E. coli
PanE active site along with the specific regions required for
recognition within the cofactor site. This data is valuable in view
of future inhibitor design, but no actual inhibitors have been
identified as yet (Ciulli et al., 2006; Ciulli et al., 2007). It is also
unclear if this information will translate to the MtPanE protein.
Assessing PanE as a Drug Target
The targetTB comprehensive in silico target identification
pipeline identified MtPanE as a high confidence target (Raman
et al., 2008). Moreover, the levels determined for MtPanE in an
Mtb proteomic analysis were the lowest of all the Pan and CoA
enzymes that could be detected (MtPanD was excluded from this
analysis) (Schubert et al., 2013). However, the panE gene is non-
essential in Mtb by Himar-1 transposon mutagenesis (Sassetti
et al., 2003; Griffin et al., 2011; DeJesus et al., 2017), most likely
due to the ability of other enzymes to perform the reduction at
sufficient levels to provide the needs for Pan biosynthesis.
Moreover, Mtb conditional knockdown mutants in panE are
refractory to growth attenuation (Evans et al., 2016). Taken
together, this points to MtPanE possibly being a poor target
in Mtb.December 2020 | Volume 10 | Article 605662
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BIOSYNTHESIS
As indicated in the previous section, most bacteria—including
Mtb—are able to synthesize their own Pan de novo, but can also
source it from the environment. Successfully targeting the Pan
biosynthetic enzymes, therefore, depends on a range of factors as
highlighted in the description of each respective enzyme. In
contrast, all organisms (barring a few rare exceptions) must
obtain CoA through biosynthesis from Pan using their own
biosynthetic machinery. This becomes especially important
during cell division, as the cellular CoA pool otherwise
remains relatively stable (Leonardi et al., 2005; Strauss, 2010).
As such, the CoA biosynthetic enzymes of Mtb have been
regarded as promising targets for antitubercular drug
development, with much energy being expended by both
industry and academic groups to identify new inhibitors of
these enzymes, especially through a number of HTS efforts.
The outcome of these and other studies are detailed in the
following section.CoaA – Pantothenate Kinase (PanK)
PanK Enzyme Structure and Mechanism
Pantothenate kinase (PanK) catalyzes the ATP-dependent
phosphorylation of Pan 2, functioning as an entry point to the
CoA biosynthesis pathway (Figure 1B). Interestingly, Mtb is one
of a few bacteria (including Bacillus subtilis) with two different,
structurally unrelated PanK enzymes (Strauss, 2010). The first,
MtPanK, is encoded by the coaA gene (Rv1092c) and belongs to
the type I PanKs that are typified by the E. coli enzyme (EcPanK).
The other, MtCoaX, is a type III PanK encoded by coaX
(Rv3603c), which is found in an open reading frame with
panD and panC. However, unlike other well-characterized type
III PanKs such as the enzymes from Pseudomonas aeruginosa
and Bacillus anthracis, the MtCoaX enzyme seems to be inactive
(Awasthy et al., 2010), and very little is known about its role (if
any) in Mtb physiology. Consequently, most of the published
studies have focused on investigating the structure and
mechanism of the type I MtPanK, with crystal structures of the
protein in complex with substrates, products, and a variety of
inhibitors (including one with CoA, the natural feedback
inhibitor) being available (Das et al., 2005; Das et al., 2006;
Chetnani et al., 2009; Chetnani et al., 2010; Chetnani et al., 2011;
Paul et al., 2017). TheMtPanK enzyme is a homodimeric P-loop
kinase with a central, seven-stranded b sheet, six of which are
parallel and the seventh anti-parallel, flanked on either side by a-
helices (Das et al., 2005; Das et al., 2006). Unique among
described type I PanKs, the enzyme is able to use both GTP
and ATP as phosphate donors with near identical efficiency
(Chetnani et al., 2010). Comparison of the EcPanK and MtPanK
structures indicates that this ability relates to small differences in
the nucleotide binding sites of the enzymes. It has been
hypothesized that this is an adaptation related to the ability of
Mtb to enter a latent state during infection (Chetnani
et al., 2010).Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 17The MtPanK kinetic parameters have been reported using
both a standard pyruvate kinase/lactate dehydrogenase (PK/
LDH) based kinase assay that couples the formation of ADP to
the oxidation of NADH, as well as using isothermal titration
calorimetry (ITC) (Kumar et al., 2007; Chetnani et al., 2009;
Venkatraman et al., 2012). Interestingly, while both methods give
similar KM values for ATP (~100–180 mM), the reported kcat
values differ more than an order of magnitude depending on the
method and the report: using the coupled assay, values of 0.61 s–1
and 5 ± 2 s–1 were reported, while using the ITC-determination
values of ~0.4–0.6 s–1 were obtained. Although there are also
other small differences in the conditions between the assays (e.g.,
pH), it is unlikely that these could account for such a large
divergence. One of the studies that used the ITC method also
determined a kcat value for EcPanK of ~1.14 s
–1 (Chetnani et al.,
2009); since this is nearly identical to the value of 1.16 s–1
reported using the coupled assay (de Villiers et al., 2014), it is
likely that the value determined by ITC and the lower value
determined using the coupled assay more closely reflects the
enzyme’s actual activity. MtPanK’s reported KM for Pan is also
higher than that of EcPanK (100–395 mM vs. ~21 mM); this
suggests that MtPanK is much less efficient than its E. coli
counterpart (Kumar et al., 2007; De Villiers et al., 2010;
Venkatraman et al., 2012).
A detailed structural analysis by Vijayan and co-workers has
suggested that, unlike what is observed for its homologue
EcPanK, the MtPanK active site does not undergo significant
structural changes during substrate binding and catalysis (Das
et al., 2006; Chetnani et al., 2009; Chetnani et al., 2010; Chetnani
et al., 2011; Paul et al., 2017). Instead, the substrates and products
change positions within a preformed binding site which
maintains its structure during catalysis (Chetnani et al., 2009;
Chetnani et al., 2010; Chetnani et al., 2011). The changes in
binding positions seem to occur due to higher affinity binding
sites becoming available as both Pan 2 and the nucleotide
triphosphate (NTP) bind, and as catalysis occurs. Specifically,
an ordered mechanism is proposed in which the NTP binds first
in a site that partially overlaps with that of Pan 2 in the initiation
complex. The subsequent binding of Pan and its movement into
the initiation complex displaces the NTP from its initial binding
position (Figure 6A). This causes a change in the NTP’s
conformation from extended to closed, with the g-phosphate
directly aligned to the 4′-OH group of Pan within the initiation
complex (Chetnani et al., 2009; Chetnani et al., 2011). Once Pan
2 is converted to P-Pan 10, the latter moves back to the initial
Pan binding site, opening up the initial NTP binding site (which
is shared with the NDP binding site) and allowing the catalytic
cycle to restart (Figure 6A). The binding sites in the initiation
complex are only accessed once both substrates have bound; this
access is mediated by the conformation of the side chain of
Arg238 which changes upon binding of Pan. In the initiation
complex, the guanidium group of Arg238 bridges the two
substrates (Chetnani et al., 2009; Chetnani et al., 2011).
An important feature of most type I PanK enzymes is that the
final product of the pathway, CoA 1, also binds to the enzyme in
such a manner that both the Pan and NTP binding sites of theDecember 2020 | Volume 10 | Article 605662
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2009). Consequently, CoA can function as a feedback inhibitor of
PanK (Leonardi et al., 2005; Strauss, 2010). Interestingly, unlike
EcPanK, heterologously expressed MtPanK purifies with CoA
bound, and the ligand could only be removed through repeated
dialysis against citrate buffer. Subsequent crystallographic
analysis indicated that this was due to CoA being displaced by
two citrate molecules (Chetnani et al., 2009). Analysis of the CoA
binding thermodynamics through isothermal titration
calorimetry (ITC) confirmed that MtPanK has a higher affinity
for CoA (Kd 4.7 mM) than does EcPanK (Kd 6.3 mM), and is
purified with ~65% of binding sites occupied with CoA
[compared to ~16% for EcPanK (Chetnani et al., 2009)].Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 18Kinetic analysis determined the Ki for the inhibition by CoA to
be 2 mM. However, the importance of CoA’s binding toMtPanK
has not been studied in a physiologically relevant context as yet;
it therefore remains uncertain what impact this has on CoA
biosynthesis in the cell, and, as such, on the development of
PanK-targeting inhibitors.
Alternate Substrates and Metabolic Activation of
Antimetabolites
Apart from being the first enzyme of both the de novo and salvage
pathways for CoA biosynthesis (Figures 1B, C), PanK also acts as
the gateway to the metabolic activation of Pan antimetabolites such






FIGURE 6 | PanK structure and substrate and inhibitor interactions. (A) Overlay of the structures of MtPanK bound to Pan (2) and the ATP analog AMPPCP (stick
structures with carbon atoms colored light green) (PDB: 2ZSE), and of MtPanK bound to P-Pan (10) and ADP (stick structures with carbon atoms colored salmon)
(PDB: 2ZSA), representing the initiation and end complexes respectively. The dashed line indicates the path of phosphoryl transfer. (B) Overlay of the structures of
MtPanK bound to Pan (2) and AMPPCP (stick structures with carbon atoms colored light green) (PDB: 2ZSE), and of MtPanK bound to CoA (1) (stick structure with
carbon atoms colored light blue) (PDB: 2ZSD), showing how the binding of CoA competitively inhibits catalysis. (C) Overlay of the structures of MtPanK bound to
Pan (2) (stick structure with carbon atoms colored gray) (PDB: 3AVO), pantothenol (54) (stick structure with carbon atoms colored blue) (PDB: 3AVP), and N9-Pan
(55) (stick structure with carbon atoms colored orange) (PDB: 3AVQ), indicating the similar binding poses for Pan and its analogues. (D) Structure of MtPanK bound
to the triazole inhibitor 56 (PDB: 4BFS) with the dashed lines showing the polar contacts between the ligand and protein residues. Key active sites residues are
shown as sticks and labeled. (E) Structure of MtPanK bound to the biaryl acetic acid inhibitor 57 (PDB: 4BFY) with the dashed lines showing the polar contacts
between the ligand, protein residues and solvent (shown as red spheres). Key active sites residues are shown as sticks and labeled. (F) Overlay of the structures of
Pan (2) and AMPPCP as bound in the initiation complex (panel a) with those of inhibitors 56 and 57 (panels D, E), showing that the latter mainly occupy the Pan
binding site.December 2020 | Volume 10 | Article 605662
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phosphorylated (Kumar et al., 2007; Moolman et al., 2014). The
potency of these compounds therefore largely depends on two
factors: the relative specificity constant of PanK for conversion of
the antimetabolite compared to Pan 2, and the relative intracellular
concentration of Pan and the antimetabolite. While a detailed
comparative kinetic analysis of MtPanK’s ability to accept a range
of Pan analogues has not been performed as has been done for other
bacterial PanKs (de Villiers et al., 2014), structural analysis of binary
complexes of the enzyme bound to Pan (2), pantothenol (54) and
N-nonyl pantothenamide (N9-Pan, 55) has been performed (Figure
6C) (Chetnani et al., 2011). This indicates that in the absence of the
NTP, all three compounds bind in a similar manner, occupying the
P-Pan (10) binding site of the end complex (Figure 6A). This is the
site where binding is proposed to first occur before these substrates
move to the binding site of the initiation complex (see above).
Combined with evidence that MtPanK phosphorylates both
pantothenol (54) and N9-Pan (55) (in the former case with ~¼
of the efficiency compared to that seen for Pan) (Kumar et al., 2007;
Chetnani et al., 2011), this suggests that it, like other type I PanKs, is
able to accept a wide range of Pan analogues as alternate substrates.
PanK Inhibitors Developed Through Rational Design
There have not been any rationally (structure-based) designed
drug candidates reported for MtPanK yet. Rational drug
development has mainly been pursued after the initial hits
have been identified.
PanK Inhibitors Identified by Screening
An HTS and several smaller screening studies have focused
primarily on identifying inhibitors of the enzyme, while others
have identifiedMtPanK as the (or one of the) target(s) of specific
drug candidates that had previously demonstrated whole
cell activity.
Venkatraman et al. (2012) adapted the standard PK/LDH-
based coupled kinase assay for HTS (Brand and Strauss, 2005).
Inhibitors were screened at 25 µM while ATP and Pan were used
at the concentration of the KM values determined for these
compounds using the coupled kinase assay (as detailed in
Section 3.1.1). Two libraries were screened, with the first (70K
compounds) focused on triazole and quinoline scaffolds, while
the second (~1 million compounds) represented a more diverse
range of molecules. The scaffolds of interest that were identified
included triazoles, thiazoles, quinoline carboxamides and biaryl
acetic acids. A high-throughput method of determining the
mechanism of inhibition was designed and verified, with the
triazoles and quinolones being found to be ATP competitive,
while the biaryl acetic acid compounds showed mixed non-
competitive inhibition (Venkatraman et al., 2012; Reddy et al.,
2014). IC50 values were determined alongside inhibition
constants for both the enzyme and the enzyme-substrate
complex. The initial hits were further improved, resulting in
the quinoline carboxamide scaffolds becoming quinolone
amides. Detailed structure-activity relationships (SARs) of the
identified classes of inhibitors were also investigated based on the
structural characterization of the exact binding interactionsFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 19within the active pocket for the triazole and biaryl classes
(Björkelid et al., 2013; Reddy et al., 2014). This shows that the
triazoles (such as compound 56) (Figure 6D) and the biaryl
acetic acids (such as compound 57) (Figure 6E) occupy a similar
binding site in the active site, but through different protein–
ligand interactions. Interestingly, both the triazoles and biaryl
acetic acids mainly overlap with the Pan binding site of the
initiation complex (Figure 6F), even though the former was
kinetically shown to be an ATP competitive inhibitor. This
observation may be explained by the inhibitors causing
Arg238—the residue acting as gatekeeper in the movement of
ligands in the active site—to take on different conformations
(compare Figures 6D, E).
The optimized set of inhibitors showed submicromolar IC50
values (Table 6, 58–61). However, since cellular ATP levels can
be up to ten times higher thanMtPanK’s determined KM for ATP
(~120 mM), IC50 values were also determined at 50×KM (6 mM)
to confirm maintained potency and inhibition mechanism
(Buchholz et al., 2001; Reddy et al., 2014). Hit potency was
significantly optimized to obtain representatives of the triazoles,
quinolones and biaryl acetic acids with IC50 values of 80 nM (58),
210 nM (59) and 22 nM (61), respectively. Unfortunately, the
ATP competitive inhibitors, namely the triazoles and quinolones,
did not display whole cell activity despite the optimized potency
(Reddy et al., 2014). They did, however, show growth inhibition
against coaA knockdown mutants with reduced expression of
MtPanK, indicating that the compounds acted on target, and that
the lack of whole cell activity was not due to poor permeability.
Ester derivatives with IC50 values lower than 1 µM in this class
showed whole-cell activity ranging between 4 µg/mL (60) and 16
µg/mL. Carboxylic acid derivatives of this class, though very
potent, did not show any whole cell activity, suggesting that they
could not cross the cell membrane (Reddy et al., 2014).
Two studies investigated natural product-derived inhibitors
active against MtPanK. Both were investigating inhibitors for
essential enzymes involved in cell wall biosynthesis, particularly
through fatty acid biosynthesis (Shilpi et al., 2015; Puranik et al.,
2018). The authors investigated inhibition against MtPanK
primarily because of its potential to activate antimetabolites.
Shilpi et al. (2015), in a purely computational study, investigated
ellagic acid and its a-L-rhamnose glycoside (Table 6, 62 and 63),
which are known to target mycolic acid biosynthesis. The two
derivatives tested had previously shown some activity against
Mycobacterium aurum in vitro and, upon docking into the Pan
binding site of MtPanK, had similar docking scores and
interacted with a greater number of residues as compared to
one of the triazole inhibitors identified in the earlier reported
HTS study (Björkelid et al., 2013). Similarly, rugosaflavonoid
derivatives were investigated for their potential MtPanK
inhibitors through an in silico docking study (Puranik et al.,
2018). The active site ofMtPanK was set up for docking through
receptor grid generation from a crystal structure with the bound
cofactor. Four compounds were identified that showed docking
scores and active site interactions similar to those seen with
isoniazid and quercetin, which were used as reference
compounds with known biological activity (albeit notDecember 2020 | Volume 10 | Article 605662
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Butman et al. Targeting Coenzyme A in Mtbnecessarily targeting PanK) (Table 6, 64–67). An XTT Reduction
Menadione Assay (XRMA) was used to determine these
compounds’ potency as whole cell inhibitors with the obtained
IC50 values ranging between 8.43 µg/mL and 17.57 µg/mL.
However, no confirmation of on-target activity was performed.
Lastly, Chiarelli et al. (2018) determined that two prodrugs
that were previously shown to inhibit the CTP synthetase PyrG,
also target MtPanK. The compounds are activated by the
monooxygenase EthA, which is mainly known for activating
other antitubercular drugs such as ethionamide (Baulard et al.,
2000; DeBarber et al., 2000). The inhibitors (Table 7, 68 – 71)
show surprising structural similarities to the biaryl acetic acid
and thiazole scaffolds previously identified for optimization byFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 21Venkatraman and co-workers, as discussed above (Venkatraman
et al., 2012; Björkelid et al., 2013). Inhibition of MtPanK was
measured by means of the PK/LDH coupled kinase assay, with a
Ki of 22.9 ± 1.3 µM being determined for the active metabolite 71
(Table 7). The compounds were shown to inhibit MtPanK by
binding to the ATP pocket, as is seen for PyrG. As multitargeting
inhibitors have a lower chance of generating resistant strains,
previous libraries used for identifying PyrG inhibitors (GSK TB-
set and Collaborative Drug Discovery (CDD) database) were
rescreened against MtPanK and several additional inhibitors
were identified through both in silico and enzymatic methods.
GSK1570606A, GSK920684A, GSK735826A (68) all had high
docking scores but only 68 was active with a Ki value of 65.3 ±TABLE 6 | Continued
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56, 58 and 59 are ATP competitive inhibitors while compounds 57, 60 and 61 are mixed noncompetitive. Compounds 62–67 are natural products and their analogues investigated by
(Shilpi, 2009; Shilpi et al., 2015) and (Puranik et al., 2018), respectively, with the latter being identified through an XRMA assay. All values are shown as reported in the original studies.Article 605662
Butman et al. Targeting Coenzyme A in Mtb4.3 µM (Table 7). CDD-934506 (Table 7, 69) was identified with
moderate activity againstMtPanK (IC50 of 40 µM), though it was
inactive against MtPyrG.
Assessing PanK as a Drug Target
The successes achieved to date in developing small molecule
inhibitors ofMtPanK with submicromolar potency suggests that
it is a highly tractable target. However, the failure of these
inhibitors to show whole cell activity led to the investigation of
this enzyme’s vulnerability in a physiological context.
Subsequent targeted knockdown studies indeed seemed to
indicate very poor vulnerability, with cells growing normally in
liquid media even when intracellular levels ofMtPanK could not
be detected by Western blotting (Reddy et al., 2014). This result
was corroborated by the finding of Evans et al. (2016) who
showed that even under conditions of maximal silencing of coaA
expression, no growth phenotype could be observed. MtPanK
was nonetheless identified as a potentially good target in the
targetTB target identification pipeline (Raman et al., 2008).
The basis for the apparent low vulnerability of MtPanK, and
the subsequent lack of success in translating potent MtPanK
inhibitors into whole cell inhibitors, remains unclear. One
potential explanation that was considered was that the type III
PanK encoded by the coaX gene could compensate for any
inhibition of MtPanK. However, under in vitro assay
conditions, the enzyme encoded by coaX was found to be non-
essential and later confirmed to be non-functional, both in vitro
and in vivo, even though it was still expressed in the organism
(Awasthy et al., 2010). An alternative reason for the poor
performance of MtPanK could be related to the control of its
activity by CoA, which is an aspect that remains unexplored.Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 22Taken together, the results in developing MtPank inhibitors
to date suggest that, until we have a better understanding of this
enzyme’s importance in the CoA pathway, its main role in TB
inhibitor drug discovery may be limited to the activation of




CoaBC Enzyme Structure and Mechanism
CoaBC, a bifunctional bacterial protein, harbors the enzymatic
activities of both PPCS and PPCDC, these being the second and
third steps in the biosynthesis of CoA (Strauss, 2010). PPCS (also
known as CoaB) catalyzes the Mg2+-dependent coupling of P-
Pan (10) and cysteine in two steps: first, cytidylation of P-Pan
with CTP to form P-Pan-CMP as activated intermediate, and
second nucleophilic displacement of cytidine monophosphate
(CMP) from the intermediate by L-cysteine to form P-PanCys
(11). P-PanCys subsequently undergoes decarboxylation of its
cysteine moiety by PPCDC (or CoaC) to yield the CoaBC
product, P-PantSH (7).
Bacterial (Type I) PPCS enzymes, exclusively utilize CTP for
activation of the P-Pan carboxylate moiety for acyl transfer,
whereas PPCS enzymes in eukaryotes (Type II PPCS) usually
prefer to use ATP (Strauss, 2010). Additionally, the fusion of
PPCS to PPCDC in the single bifunctional CoaBC protein is an
occurrence restricted to bacteria, while the eukaryotic PPCS and
PPCDC enzymes are generally expressed by two different genes
as separate monofunctional proteins. The Mtb enzymeTABLE 7 | Structures and inhibition characteristics of MtPanK inhibitors identified through resistance mechanismsa.
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by the coaBC gene (Rv1391) like its other bacterial counterparts.
The crystal structures of E. coli PPCS (CoaB domain of the E.
coli CoaBC protein) in complex with several ligands (Stanitzek
et al., 2004), human PPCS (Manoj et al., 2003), yeast PPCS
(Zheng et al., 2019) and human PPCDC (Manoj and Ealick,
2003) have been solved and analyzed, though the three-
dimensional structures of the Mtb CoaBC (MtCoaBC) or its
constituent domains remain unknown. However, the coordinates
of the structure of the M. smegmatis PPCS (MsPPCS), i.e. the
CoaB domain of the M. smegmatis CoaBC (MsCoaBC) was
previously deposited (PDB: 4QJI). This structure clearly shows
the dimeric nature and subunit interaction of the CoaB domains,Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 23as well as the active site pocket with CTP bound (Figure 7A).
Recently a preprint describing the structures of both the full
MsCoaBC and its CoaB domain was published (Mendes et al.,
2019). The solution of a bacterial CoaBC crystal structure at 2.5
Å resolution is an important achievement, as it provides the first
glimpse of the overall shape and structure of this multimeric
protein. The structure shows that the protein is a dodecamer that
takes on the shape of a tetrahedron, with the CoaB domains
forming dimers at its six edges, and the CoaC domains forming
trimers at its four vertices (Figure 7B). The two domains are
joined by a loop region that interacts closely with each of them.
The active site of the PPCDC enzyme (CoaC domain) lies at the






FIGURE 7 | CoaBC structure and inhibitors. (A) Structure of MsPPCS, i.e., the CoaB domain of the M. smegmatis CoaBC (PDB: 4QJI), showing the dimer
interaction in the cartoon and the active site pocket with CTP and Mg2+ bound in the surface model. The two subunits are shown in different colors. (B)
Schematic representation of the dodecameric MsCoaBC structure (Mendes et al., 2019), which takes on the shape of a tetrahedron, with the CoaB domains
forming dimers at its six edges, and the CoaC domains forming trimers at its four vertices. In this representation only two CoaBC proteins (in cyan and orange)
are shown to highlight the CoaBC interaction, with one CoaC trimer shown at the top vertex. (C) Structures of antimetabolite inhibitors of the PPCS activity of
CoaBC proteins. 4′-Phosphopantothenol (72) and 4′-phospho-CJ-15,801 (73) are formed through the action of PanK enzymes on the corresponding Pan
analogues, with 73 being transformed in situ into the nonreactive reaction intermediate 74, that is a potent PPCS inhibitor. (D) Nonreactive bisubstrate inhibitors
(structural mimics of the acyl nucleotide intermediate of PPCS) of several bacterial PPCS enzymes (Patrone et al., 2009). (E) Structures of allosteric inhibitors of
the PPCS activity of MtCoaBC discovered through an HTS (Mendes et al., 2019). (F) Structures of three potent Mtb CTP synthetase (PyrG) inhibitors from
screening a GlaxoSmithKline library which are proposed to also affect MtCoaBC (Esposito et al., 2017). (G) Structure of compound 8918 (82), an inhibitor of Mtb
phosphopantetheinyl transferase (PptT) that also shows pleotropic effects on CoA biosynthetic intermediate levels. It is proposed that this occurs through
inhibition of MtCoaBC, although direct evidence of this remains lacking (Ballinger et al., 2019).December 2020 | Volume 10 | Article 605662
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smegmatis CoaB does not and requires stabilisation by the CoaC
domain (Kupke, 2002; Chan et al., 2019; Mendes et al., 2019).
The PPCS active site is at the dimer interface (dimerization takes
place between the CoaB domains that point outward from the
CoaC trimer, i.e., adjacent trimers dimerize via CoaB domains)
and is enclosed by a loop from an opposing protomer (Mendes
et al., 2019). The authors confirmed that like the MsCoaBC, the
MtCoaBC protein is a dodecamer as well, with the two proteins
having molecular weights of 523 kDa and 537 kDa, respectively
(Mendes et al., 2019).
CoaBC Inhibitors Formed Through Metabolic
Activation of Antimetabolites
In 2007, it was first demonstrated that pantothenol (54) acts as an
alternate substrate for MtPanK, forming 4′-phosphopantothenol
(72) (Figure 7C) (Kumar et al., 2007). This subsequently acts as a
competitive inhibitor of CoaBC, preventing CoA biosynthesis from
continuing. This was demonstrated by means of an activity analysis
making use of an assay relying on the conversion of radiolabeled
P-Pan (10). In the assay, varying amounts of inhibitor were
incubated with the enzyme and substrates for 2 min, after which
the reaction was stopped by heating denaturation and the products
were separated via thin-layer chromatography (TLC). New spots
were identified by ESI-MS and conversion was calculated
by determining the amount of product formed using
radiodensitometry analysis. In this manner, an IC50 value of 63
µM pantothenol was determined for inhibition ofMtCoaBC activity
(Kumar et al., 2007). Based on these findings the authors postulate
that pantothenol is likely to inhibit the growth of other bacteria
using a similar mechanism of action (metabolic activation by PanK
followed by inhibition of the PPCS activity of the CoaBC protein by
4′-phosphopantothenol).
A natural product analogue of Pan (2), CJ-15,801, was shown
to exhibit selective, micromolar whole cell activity against drug
resistant strains of S. aureus, whereafter it was identified as a
tight-binding inhibitor of EcPPCS and SaCoaBC (Sugie et al.,
2001; van der Westhuyzen et al., 2012). Its mechanism of
inhibition was determined to proceed via phosphorylation of
CJ-15,801 by SaPanK (i.e., metabolic activation) to form 4′-
phospho-CJ-15,801 (73), and subsequent formation of the
corresponding cytidylylated intermediate (74) by PPCS (Figure
7C). This intermediate was shown to be unreactive, and therefore
exhibited excellent inhibition by acting as a structural mimic of
the natural reaction intermediate, with Ki values of 164.3 nM for
EcPPCS and 13 nM for SaCoaBC (van der Westhuyzen et al.,
2012). The study demonstrated that CJ-15,801 is selective for S.
aureus because of the unique substrate specificity of the type II
SaPanK; type I PanKs (including those of E. coli and Mtb) does
not act on CJ-15,801, and therefore metabolic activation does not
occur. However, it may be possible to circumvent this
requirement for metabolic activation by preparing prodrug
versions of the activated inhibitor 73 in which the polar
phosphate and carboxylate groups are protected with labile
esters groups. This strategy has been successfully used to
convert the natural product fosmidomycin—an inhibitor of
Mtb 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR)Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 24with a polar phosphonate moiety—into cell-permeable whole cell
inhibitors (Wang and Dowd, 2018).
CoaBC Inhibitors Developed Through Rational
Design
To date, there have been no reports on any MtCoaBC inhibitors
developed by rational design approaches. This is likely due to the
lack of an available crystal structure, and may likely change with the
report of the structure of the MsCoaBC protein. Nonreactive
analogues of the 4′-phosphopantothenoyl-nucleotidylate
intermediate formed during the PPCS reaction have been
explored as inhibitors of Enterococcus faecalis, Streptococcus
pneumonia, and E. coli PPCS enzymes (Patrone et al., 2009). A
series of structural mimics of the intermediate were designed and
synthesized. Significantly, compounds 75 and 76 (Figure 7D) were
found to have up to 1000-fold and 740-fold selectivity, respectively,
for bacterial PPCS over the human enzyme in vitro, both with IC50
values in the nanomolar range (Patrone et al., 2009). For these
analyses, a continuous spectrophotometric assay was used that
couples the production of pyrophosphate in the first step of the
reaction to the oxidation of NADH through the intermediacy of six
coupling enzymes. In this manner the inhibitors were identified as
being tight-binding and non-competitive with CTP. Furthermore,
75 was shown to undergo both slow association and dissociation
with the enzyme and was subsequently classified as a slow-onset
inhibitor. This was supported by analysis of the progress curves that
showed a time-dependent decrease in reaction rate and plots of kobs
against inhibitor concentration that were linear. Unfortunately, the
compounds in this study failed to exhibit activity against bacterial
growth, likely due to a lack of cell penetration because of the
presence of the polar and ionized terminal phosphate group.
CoaBC Inhibitors Identified by Screening
As part of the recent report on the structures of theM. smegmatis
CoaB and CoaBC proteins, an HTS of 215K compounds was
performed against MtCoaBC using an endpoint assay that
determines the amount of pyrophosphate formed after two
hours (Mendes et al., 2019). The most potent hits were
characterized further by determining IC50 values using the
EnzCheck coupled pyrophosphate assay. A search of
commercially available analogues of the initial hits resulted in
the identification of two compounds (hydroxylated diphenyl
ketone 77 and chromone 78, Figure 7E) with sub-micromolar
IC50 values (280 and 80 nM, respectively). It should be noted that
these assays were performed using 32 nM enzyme, i.e., the
determined IC50 values are less than 10-fold the enzyme
concentration used. This would indicate tight-binding
inhibition, and standard steady state kinetic analysis would not
apply in such a case. These values should therefore be
understood taking this into consideration.
Co-crystallization ofMsCoaBC in complex with CTP revealed
that 77 binds in a deep cavity that links to the active site. This
cavity, which is located at the interface of the CoaB dimer, is
obstructed when the native P-Pan (10) substrate is not bound. It
was further shown that two of these extended pockets are present
in each CoaB dimer. The opening and closing of these allosteric
binding sites are largely mediated by a highly conserved arginineDecember 2020 | Volume 10 | Article 605662
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cysteine and is known to be intimately involved in the conversion
of P-Pan-CMP to P-PanCys (11). Further elucidation of these
compounds’ mechanism of inhibition led to the hypothesis that
the substrate-bound enzyme is stabilized upon binding of the
inhibitors to the allosteric site as this locks the side chain of
Arg207 in place, thus removing the enzyme from the catalytic
cycle (Mendes et al., 2019). The inhibitors did not display whole
cell activity, though some moderate to low activity was displayed
in albumin-free media. It was suggested that the difference
between the enzymatic and whole cell results could be due to
albumin binding, efflux, low permeation or metabolization. In
summary, this novel allosteric site located at the dimer interface
provides the potential for inhibiting the PPCS activity of
MtCoaBC (Mendes et al., 2019).
In a fragment-based screen utilizing differential scanning
fluorimetry and NMR, an aryl sulfonamide was identified as a
potential inhibitor of EcPPCS (Chan et al., 2019). Several simpler
aromatic derivatives of this fragment were then synthesized and
screened with native MS (ESI-MS from a non-denaturing solvent)
that identified five hits. These results were further corroborated by
means of a coupled enzymatic assay (using the EnzCheck
pyrophosphate assay kit) that monitors the production of
pyrophosphate in the presence of inhibitors. The inhibitors
identified as hits by native MS were tested at 1 mM, and their
relative amount of inhibition of PPCS activity was found to range
between 29 and 92%. Inhibition values of those compounds not
identified as hits in the native MS screen were below 29% (Chan
et al., 2019).
Following the identification of the Mtb CTP synthetase PyrG
as a new antiTB drug target, a GlaxoSmithKline compound
library was used in an HTS study to identify new CTP
synthetase inhibitors (Esposito et al., 2017). This resulted in
the identification of a series of 4-(pyridine-2-yl) thiazole
analogues with activity against Mtb PyrG. The three most
active compounds exhibited low micromolar Ki values (79–81,
Figure 7F). Additionally, these compounds demonstrated
specificity for CTP synthetases, lacking activity against a panel
of prokaryotic and eukaryotic kinases (Esposito et al., 2017). The
authors proposed that these compounds would also impact the
activity of MtCoaBC due to its requirement of CTP for activity.
While it was shown that the PyrG inhibitors decreased the
incorporation of acetate into cells, indicating a pleotropic
effect, no direct impact on MtCoaBC activity was determined
or demonstrated.
Recently, the amidino-urea 8919 (82) was discovered to
inhibit phosphopantetheinyl transferase (PptT) (Figure 7G).
PptT is the enzyme responsible for post-translational activation
of the apo-acyl carrier protein (apo-ACP) into its active holo
form through the transferal of CoA’s P-PantSH moiety of a
conserved Ser residue in the protein. The authors proposed 82
might also inhibitMtCoaBC based on the impact of the inhibitor
onMtb’s metabolism through a metabolomics analysis (Ballinger
et al., 2019). However, similar to the PyrG inhibitors, direct
evidence of inhibition of any of MtCoaBC’s activities by 82
remains lacking.Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 25Finally, a team from the University of Michigan (UM)
reported the results of an HTS performed to identify inhibitors
of bacterial PPCS enzymes (Gómez-Rodrıǵuez et al., 2020). They
used the malachite green end point assay for pyrophosphate
formation to screen the UM Center for Chemical Genomics
natural product extract (NPE) library; specifically, 11,000 NPEs
derived from marine microbes were screened. After counter-
screening, 22 strains producing inhibitors of the S. pneumoniae
PPCS (SpPPCS) were identified. Fractionation and structural
characterization identified the adipostatins, natural products that
share a common alkylresorcinol structure, as the active PPCS
inhibitors in the NPEs. Subsequent anti-microbial growth assays
identified adipostatin E as being the most potent, with an IC50
value of 930 nM against SpPPCS and whole cell activity against
five Gram-positive pathogens, with IC50 values between 3.4 and
15.6 mM. Gram-negative bacteria was resistant to inhibition.
Activity against mycobacteria was not tested.
PPCDC Inhibitors Developed Through Rational
Design or Screening
No inhibitor has been reported to act on the PPCDC activity of
MtCoaBC to date. The only known inhibitor of any PPCDC
activity is a cyclopropyl-substituted 4′-phospho-N-(1-
mercaptomethyl-cyclopropyl)-pantothenamide (P-PanDSH)
that was shown to act as a mechanism-based inhibitor of the
human PPCS enzyme (Strauss et al., 2004).
Assessing CoaBC as a Drug Target
As described above, Evans et al. (2016) created a panel of
conditional knockdown mutants in genes encoding six
potential targets within the CoA pathway (PanB, PanE, PanK,
CoaBC, CoaD, and CoaE) and used to assess the viability of Mtb.
From this seminal study, it was shown that depletion of coaBC,
both in vitro and in vivo in infected mice, was the only
bactericidal target in the CoA biosynthetic pathway. This
important work inspires studies examining CoaBC as a novel
drug target. Although limited progress has been made on the
discovery of inhibitors to date, the significant differences between
bacterial and mammalian enzymes, the recent discovery of an
allosteric site that remains unexplored by rational drug design,
and the importance of CoaBC to Mtb viability in vivo all ensure




PPAT Enzyme Structure and Mechanism
Phosphopantetheine adenylyltransferase (PPAT) catalyzes the
reversible Mg2+-dependent adenylylation of P-PantSH (7) to
form DePCoA (12) and pyrophosphate. The E. coli enzyme
has been shown to tightly bind CoA, which results in
inhibition of its activity (Miller et al., 2010); a similar result is
obtained for the Mtb enzyme (Wubben and Mesecar, 2010). As
such, PPAT has been proposed as a second point of feedback
control by CoA on the pathway (after PanK) (Jackowski and
Rock, 1984; Strauss, 2010). A wealth of detailed biochemical andDecember 2020 | Volume 10 | Article 605662
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tuberculosis (MtPPAT) encoded by the coaD gene (Rv2965c),
providing detailed characterization of the active site and insight
into the inhibitory mechanism of the enzyme. The structures
include: the three-dimensional structure of apoMtPPAT (Morris
and Izard, 2004; Timofeev V. I. et al., 2012; Timofeev V. et al.,
2012), MtPPAT in complex with substrates P-PantSH (7) and
ATP (or its non-hydrolyzable analogue, AMPCPP) (Wubben
and Mesecar, 2010; Timofeev V. et al., 2012), MtPPAT in
complex with the feedback inhibitor CoA (Timofeev et al.,
2010; Wubben and Mesecar, 2011; Timofeev V. I. et al., 2012),
and MtPPAT in complex with reaction product DePCoA
(Timofeev V. I. et al., 2012).
Structurally, MtPPAT is part of the nucleotidyltransferase a/
b phosphodiesterase superfamily, existing as a homohexamer,
composed of six chemically identical subunits in its native state
(Izard and Geerlof, 1999; Timofeev et al., 2010). Each subunit
consists of 161 amino acid residues, with a five-stranded parallel
b-sheet and six a-helices. The b-strands are linked by the a-
helices in an alternating b/a pattern, resulting in the formation
of a Rossman fold, the same nucleotide-folding pattern found in
MtPanC (Rao and Rossmann, 1973; Timofeev V. I. et al., 2012).
The active site of each subunit is comprised of a large cavity
exposed to a solvent-filled channel; consequently, the entrance
region of the channel is a functionally critical region of the
enzyme that influences the rate of substrate access. A flexible
loop consisting of residues 36–46 is thought to be responsible for
restricting entrance to the active site. It contains Lys41, aFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 26conserved residue essential for stabilizing the pentavalent
transition state of the reaction. Additionally, a group of
negatively charged residues surround the entrance to the
channel, specifically at the trimer–trimer interface, preventing
the diffusion of negatively charged molecules from one trimer to
another (Timofeev et al., 2010).
Previous studies have shown that in structures of MtPPAT in
complex with ATP and DePCoA (12), but not CoA (1) and P-
PantSH (7), conformational changes occur in a small region of the
polypeptide chain upon ligand binding. These rearrangements are
mainly confined to residues 89–96, located at the perimeter of the
solvent channel, which in turn cause alteration in the size of the
solvent-filled channel and the overall quaternary structure
(Timofeev V. et al., 2012). Interestingly, CoA controls the rate of
the PPAT-catalyzed reaction through a feedback mechanism, in
which CoA occupies the active site at high concentrations, causing
the reaction to be terminated. Since the structures of CoA and
DePCoA only differs in the presence of the additional 3′-phosphate,
this raises the question as to how the structures are distinguished as
to prevent product inhibition by DePCoA. Analysis of the two
crystal structures in complex withMtPPAT shows that the position
of the pantetheine chain of both CoA and DePCoA are analogous;
however, a significant distance between the amino groups of the
adenylate group is observed for these two molecules (Timofeev
et al., 2012). Additionally, DePCoA is located in a deep pocket of the
active site of MtPPAT (Figure 8A), unlike that of CoA. A detailed
presentation of binding interactions of the enzyme with the reaction




FIGURE 8 | MtPPAT structure and selected PPAT inhibitors. (A) MtPPAT complexed with the reaction product DePCoA 12 shown as a stick structure (PDB: 3RBA)
(Timofeev V. I. et al., 2012). (B) The binding interactions of DePCoA 12 in the active site of MtPPAT (PDB: 3RBA). Hydrogen bonding interactions with the indicated
active site residues are shown as black dashed lines. (C) Inhibitors of E. coli and P. aeruginosa PPAT displaying sub-micromolar activity (Moreau et al., 2018).
(D) Selective inhibitors of MtPPAT identified through in silico screening, which are predicted to prevent substrate binding at the active site (Podshivalov et al., 2017).December 2020 | Volume 10 | Article 605662
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While no inhibitors have been reported for MtPPAT using
structure-based approaches, inhibitors have been described for
EcPPAT, its homologue from E. coli (Zhao et al., 2003; Miller
et al., 2010; Moreau et al., 2018; Skepper et al., 2018; Liyanage et al.,
2019; Wang et al., 2020). The two homologues share 44% identity
and 77% similarity in their amino acid sequences, and both exist as
hexamers in their active form (Timofeev et al., 2010). While several
differences are present between the two structures, such as the
number of subunits involved in ligand binding, evaluation of
EcPPAT inhibitors can guide future design of compounds to
inhibit MtPPAT. Recently, a fragment-based strategy facilitated by
crystallography revealed several highly potent compounds (83 and
84, Figure 8C) with nanomolar activity against EcPPAT and P.
aeruginosa PPAT (PaPPAT), and moderate cellular activity against
the efflux-deficient E. coli DtolC mutant (Moreau et al., 2018;
Skepper et al., 2018). Inhibitor development studies of other
bacterial PPAT enzymes, including those from S. aureus, S.
pneumoniae, and H. pylori have also been performed, but none of
these have led to the development of clinical candidates (De Jonge
et al., 2013; Cheng et al., 2013). In the case of the S. aureus PPAT,
potent enzyme inhibitors failed mainly due to poor drug-like
properties (e.g., low solubility and high clearance rates) that could
not be improved without loss in potency (De Jonge et al., 2013).
PPAT Inhibitors Identified Through Screening
In a recent study, four compounds were identified as selective
inhibitors of MtPPAT found by virtual screening methods.
Podshivalov et al. (2017) employed the Mcule online drug
discovery platform to perform a docking-based virtual screen
of more than four million compounds. The potency of lead
compounds was analyzed based on the Vina scoring function
(Lipinski et al., 2001; Trott and Olson, 2010). Four of the best-
scoring compounds (85–88, Figure 8D), all of which satisfy
Lipinski’s rules, were further investigated by molecular dynamics
simulation to analyze their relative positions and binding
interactions in the enzyme active site. Compounds 85–88 were
all found to interact with residues in the active site ofMtPPAT, in
addition to occupying a similar volume to that of native
substrates (Podshivalov et al., 2017). Interestingly, binding of
these ligands did not lead to any conformational change in active
site residues of the enzyme. This differs to what is seen during
binding of MtPPAT’s substrates (ATP and DePCoA) and its
feedback inhibitor CoA, all of which leads to significant
conformational rearrangements. When docked to the enzyme’s
active site, the compounds block substrate access to the active
site, indicating that they would be able to act as inhibitors of
MtPPAT (Podshivalov et al., 2017). This study suggests
that inhibitors of MtPPAT could be designed as effective
antimycobacterial agents with high selectivity.
Assessing PPAT as a Drug Target
The vast structural and mechanistic studies that have been
reported for MtPPAT demonstrate its potential as a target for
antitubercular drug development. However, given the overall
lack of inhibitors designed to date, there remains minimal
knowledge about the potential efficacy of such compounds.Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 27Moreover, the targeted knockdown study conducted by Evans
et al. (2016) indicated that MtPPAT shows low vulnerability, as
its depletion by transcriptional silencing could not reduce the
protein to levels low enough to produce a growth phenotype.
MtPPAT is also not included in the list of targets identified by
targetTB pipeline (Raman et al., 2008). Taken together, this
would suggest that MtPPAT is not a preferred target for
antitubercular drug development at the moment.
CoaE – Dephosphocoenzyme A Kinase
(DPCK)
DPCK Enzyme Structure and Mechanism
DPCK, thefinal enzyme in theCoAbiosynthetic pathway, catalyzes
the ATP-dependent phosphorylation of DePCoA at the 3’-position
of the ribose ring to generate CoA (1) (Strauss, 2010). Crystal
structures of various bacterial DPCK proteins have been
determined, yet the three-dimensional structure of Mtb DPCK
(MtDPCK), encodedbythe coaEgene(Rv1631), remainsunknown.
Thus, homology modeling and sequence analysis using close
structural homologues of MtDPCK has been used in an attempt
to elucidate the structure and function of this enzyme (Walia et al.,
2009; Walia et al., 2011; Walia and Surolia, 2011).
DPCK enzymes belong to the NTP hydrolase superfamily,
which is known to share several structural features even while
only exhibiting minor sequence similarities (Walia et al., 2011).
Most significant of these is the inclusion of a phosphate binding-
loop, or P-loop, aswell as the overall foldof the protein consisting of
three domains. In the work of Walia et al. (2009), an exception to
this prototype was discovered forMtDPCK, in which an additional
C-terminal domain that belongs to a family of proteins of unknown
function, UPF0157, was identified and characterized. It was found
that the UPF0157 domain plays an essential role in facilitating the
expression andproper foldingof theN-terminal domain,whichwas
incapable of independently reaching its biologically functional
conformation (Walia et al., 2009).
Biochemical and biophysical characterization of MtDPCK
was reported by Walia et al. (2009) following the construction
of a mycobacterial DPCK homology model. The N-terminal
domain was modelled after the structurally similar E. coli
homologue (32.7% identity, 54.7% similarity), while the E.
faecalis enzyme was used as a template to model the C-
terminal domain (25.5% similarity). EfDPCK also belongs to
the UPF0157 family of proteins and no other crystal structures
were available for this domain (Walia et al., 2009). This putative
structure was then used to characterize the binding affinity of
MtDPCK to its substrates, DePCoA and ATP, and subsequently
elucidate the order of substrate binding. The results revealed that
MtDPCK follows an ordered mechanism, beginning with the
binding of DePCoA and followed by ATP, suggesting that a
conformational change may occur upon binding of DePCoA that
results in more favorable binding of ATP (Walia et al., 2009).
Binding and kinetic studies revealed that CTP binds tightly to
MtDPCK. Interestingly, when tested for its ability to act as a
phosphate donor, CTP was unsuccessful in binding to the
DePCoA–DPCK complex, but was found to inhibit MtDPCK
(Walia et al., 2009). This was explained through the docking of
CTP and DePCoA to DPCK, which demonstrated the overlap ofDecember 2020 | Volume 10 | Article 605662
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that CTP acts as a metabolic regulator. Since ATP is the
phosphorylating agent, when the ratio of ATP/CTP in the cell is
significantly reduced in response to stress, the CTP level effectively
limits the amount of CoA produced (Walia et al., 2009).
DPCK Inhibitors Developed Through Rational Design
or Screening
To date, there are no reported inhibitors ofMtDPCK. Due to the
significant homology in both sequence and in structure between
bacterial DPCKs and the DPCK domain of the bifunctional
human coenzyme A synthase (CoASy) that has both PPAT and
DPCK activity, the ability to develop selective inhibitors of the
microbial DPCK enzymes may pose a significant challenge
(Aghajanian and Worrall, 2002; Daugherty et al., 2002;
Zhyvoloup et al., 2002; Moolman et al., 2014).
Assessing DPCK as a Drug Target
With no inhibitors of MtDPCK being reported to date, the
assessment of its suitability as a target mainly relies on the
conditional knockdown mutant study of Evans et al. (2016) and
the assessment of the targetTB target identification pipeline.
Depletion of MtDPCK through transcriptional silencing of coaE
resulted in a progressive reduction of growth and a bacteriostatic
phenotype, suggesting that inhibitorsofMtDPCKhavea reasonable
prospect of translating into whole cell growth inhibitors. This
analysis is corroborated by the identification of MtDPCK as one
of 451 high confidence targets by targetTB (Raman et al., 2008).
However, as pointed out above, the high sequence and structural
homology between bacterial DPCK enzymes and the DPCK
domain of eukaryotic CoASy proteins does suggest that selectivity
might be difficult to achieve, which would in turn raise concerns
regarding toxicity. In this context, it should be noted that the
targetTB assessment does include a comprehensive comparative
binding pocket analysis based on available structural information
for the Mtb and human proteomes, and thatMtDPCK passed this
specific screen (Raman et al., 2008). In addition, several other
factors suggest that it could be possible to mitigate the potential
challenge of selective inhibitor development. These include the
possibilityof exploiting theaspects related to thebifunctionalnature
of the human CoASy enzyme, and the fact that humans have a
second, monofunctional DPCK which remains uncharacterized
(Vozza et al., 2017; Giessner et al., 2018). This DPCK could
provide redundancy that may counter any potential toxic effects
from the use of DPCK-targeting inhibitors. Finally, it may be
possible to target the regulation of MtDPCK instead of its
catalytic activity, to thereby circumvent any potential problems
with selectivity.CONCLUSION
We have sought to provide a detailed overview of the current
status of the Pan and CoA biosynthetic enzymes in the context of
antiTB drug development. Although there is considerable
support in the form of genetic and in silico validation studies
of several of the pathway enzymes being high confidence drugFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 28targets, and although small molecule inhibitors with nanomolar
potency has been developed in the case of some enzymes,
unfortunately very few of these compounds show whole cell
activity, with none being active in vivo. Yet, the information
summarized here suggests that the CoA pathway remains a target
with high potential for antiTB drug development. Specifically,
MtPanD and MtCoaBC currently appear to be the most likely
targets to yield positive results; the former based on the recent
findings that link the activity of the well-known antiTB agent
PZA (52) to inhibition and/or degradation of MtPanD, and the
latter based on the bacteriocidal effects and in vivo efficacy of
targeted depletion of MtCoaBC. MtPanC also remains a worthy
target based on the large number of leads for further
development of improved inhibitors, while the inhibitory
potential of MtDPCK remains largely unexplored.
An important aspect of the development of inhibitors targeting
theMtbCoApathway enzymes is that it shouldnot be considered in
isolation. Instead, such compounds are highly likely to be successful
when used in combination with inhibitors of any number of
enzymes that depend on CoA. For example, PptT inhibitors such
as 8919 (82) (Ballinger et al., 2019), and inhibitors of enzymes
involved in the glyoxylate shunt (such as isocitrate lyase, ICL)
should both work synergistically with compounds reducing CoA
levels (Wellington andHung, 2018). This should also be the case for
pantothenamides that are converted to CoA antimetabolites that
target CoA utilizing enzymes (as seems to be the case in themalaria
parasite, Plasmodium falciparum) (Schalkwijk et al., 2019).
Considering that combination treatments have been the mainstay
of antiTB drug regimens,multi-target inhibitors that all have a CoA
producing or utilizing enzyme in the crosshairs could prove to be
the breakthrough that is so urgently needed in the development of
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